1
|
Barakat L, Lagreula M, Zermati R, Laborier F, Chiriac AM, Neukirch C. Recurrent Localized Erythema Scarlatiniforme Desquamativum Recidivans Induced by Iodinated Contrast Media. J Allergy Clin Immunol Pract 2024; 12:1344-1345. [PMID: 38466257 DOI: 10.1016/j.jaip.2024.02.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 02/13/2024] [Accepted: 02/14/2024] [Indexed: 03/12/2024]
Affiliation(s)
- Leyla Barakat
- Service de Pneumologie A, APHP Hôpital Bichat, Paris, France.
| | - Marie Lagreula
- Unité Transversale d'Allergologie, Service de Dermatologie, CHU Nîmes Carémeau, Place du Professeur Robert Debré, Nîmes, France
| | - Raphaël Zermati
- Service de Pneumologie A, APHP Hôpital Bichat, Paris, France
| | - Félix Laborier
- Service de Pneumologie A, APHP Hôpital Bichat, Paris, France
| | - Anca Mirela Chiriac
- Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier and IDESP Montpellier, Montpellier, France
| | - Catherine Neukirch
- Service de Pneumologie A, APHP Hôpital Bichat, Paris, France; Université de Paris Cité, Inserm 1152, Paris, France
| |
Collapse
|
2
|
Chéron N, de Chaisemartin L, Aubert S, Laborier F, Montravers P, Neukirch C, Gouel-Chéron A. Are changes in antibiotic prophylaxis recommendations responsible for an increased risk of cefazolin allergy? Anaesth Crit Care Pain Med 2024; 43:101349. [PMID: 38278354 DOI: 10.1016/j.accpm.2024.101349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 12/28/2023] [Accepted: 12/28/2023] [Indexed: 01/28/2024]
Abstract
BACKGROUND The first line of prevention of surgical site infection relies on the timely administration of antibiotic prophylaxis. First- and second-generation cephalosporins are the most recommended antibiotics in elective surgery. The incidence of cefazolin allergy has increased worldwide over the years. The sensitization mechanism of cefazolin is currently unknown, and data supporting cross-reactivity between penicillins and cephalosporins are lacking. Sensitization could occur through previous exposure either to cefazolin or to structurally related chemical agents. The objective of this study was to evaluate sensitization agents towards cefazolin. METHODS The OpenBabel chemoinformatics toolbox was used to search for similarities between cefazolin and other molecules in an extensive drug database. Using the pholcodine-rocuronium similarity score as a threshold, we selected drugs with the most similar structure to that of cefazolin. Exposure to those drugs and cefazolin was assessed in a cohort of patients with skin test-proven cefazolin allergy at a specialized allergy centre via a self-administered anonymous questionnaire. RESULTS Using the pholcodine-rocuronium similarity score as a threshold (score≥0.7), 42 molecules were found to be similar to cefazolin (all cephalosporins). Only 8 were marketed in France. None of the 14 cefazolin-allergic patients who answered the questionnaire (65% female, median age 56 years) reported exposure to any identified antibiotics. In contrast, 11 (78%) had at least one previous surgery requiring cefazolin before the index case. CONCLUSION Direct previous cefazolin exposure was identified in 78% of cefazolin-allergic patients. Cefazolin started to take a central place in antibiotic prophylaxis after 2010, when cefamandole usage decreased drastically. Changes in antibiotic prophylaxis over the past 14 years in France could have been the turning point for the increased incidence of cefazolin allergy.
Collapse
Affiliation(s)
- Nicolas Chéron
- PASTEUR, Département de Chimie, École Normale Supérieure, PSL University, Sorbonne Université, CNRS, 75005 Paris, France
| | - Luc de Chaisemartin
- Antibody in Therapy and Pathology, Pasteur Institute, UMR 1222 INSERM, Paris, France; Université Paris-Saclay, Inflammation, Microbiome and Immunosurveillance, INSERM, 92290 Orsay, France
| | - Simon Aubert
- Paris City University, Paris, France; Immunology Department, "Autoimmunity, Hypersensitivities and Biotherapies", DMU BIOGEM, Bichat Hospital, AP-HP, Paris, France
| | - Felix Laborier
- Pneumology A unit, Bichat Hospital, AP-HP, Paris, France
| | - Philippe Montravers
- Paris City University, Paris, France; Anesthesiology and Critical Care Medicine Department, DMU PARABOL, Bichat Hospital, AP-HP, Paris, France; Université Paris Cité, INSERM 1152, Paris, France
| | - Catherine Neukirch
- Pneumology A unit, Bichat Hospital, AP-HP, Paris, France; Université Paris Cité, INSERM 1152, Paris, France
| | - Aurélie Gouel-Chéron
- Antibody in Therapy and Pathology, Pasteur Institute, UMR 1222 INSERM, Paris, France.
| |
Collapse
|
3
|
Bernardinello N, Crestani B, Spagnolo P, Ghanem M, Homps-Legrand M, Morer L, Goletto T, Frija-Masson J, Bancal C, Hurtado-Nedelec M, de Chaisemartin L, Debray MP, Neukirch C, Taillé C, Ba I, Kannengiesser C, Lainey E, Abels A, Vankann L, Beier F, Borie R. Is telomere length a predictor of long-term survival in patients with COVID-19 pneumonia? Respir Med Res 2023; 84:101048. [PMID: 37826871 DOI: 10.1016/j.resmer.2023.101048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/05/2023] [Accepted: 09/05/2023] [Indexed: 10/14/2023]
Affiliation(s)
- Nicol Bernardinello
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Bruno Crestani
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Paolo Spagnolo
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Mada Ghanem
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France; Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Méline Homps-Legrand
- Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Lise Morer
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Tiphaine Goletto
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Justine Frija-Masson
- Service de Physiologie Explorations Fonctionnelles, APHP, et Université de Paris, Inserm Neurodiderot F-75018 France
| | - Catherine Bancal
- Service de Physiologie Explorations Fonctionnelles, APHP, et Université de Paris, Inserm Neurodiderot F-75018 France
| | | | - Luc de Chaisemartin
- Universite Paris-Sud, Université Paris-Saclay, APHP, Laboratoire d'immunologie, Hôpital Bichat, Paris, France, Inserm, Châtenay-Malabry, France
| | - Marie Pierre Debray
- Laboratoire d'excellence INFLAMEX, Universite de Paris, Inserm, U1152, Paris, France
| | - Catherine Neukirch
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Camille Taillé
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France
| | - Ibrahima Ba
- Université de Paris, INSERM 1152, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de génétique, DHU APOLLO, Paris, France
| | - Caroline Kannengiesser
- Université de Paris, INSERM 1152, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de génétique, DHU APOLLO, Paris, France
| | - Elodie Lainey
- Hematology Laboratory, Robert Debré Hospital-Assistance Publique-Hôpitaux de Paris (APHP), INSERM UMR 1131-Hematology University Institute-Denis Diderot School of Medicine, Paris, France
| | - Anne Abels
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Lucia Vankann
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Fabian Beier
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany
| | - Raphaël Borie
- Service de Pneumologie A Hôpital Bichat, APHP, Paris, France, Université Paris Cité, Inserm, PHERE, Université Paris Cité, 75018 Paris, France.
| |
Collapse
|
4
|
Beydon N, Taillé C, Corvol H, Valcke J, Portal JJ, Plantier L, Mangiapan G, Perisson C, Aubertin G, Hadchouel A, Briend G, Guilleminault L, Neukirch C, Cros P, Appere de Vecchi C, Mahut B, Vicaut E, Delclaux C. Digital Action Plan (Web App) for Managing Asthma Exacerbations: Randomized Controlled Trial. J Med Internet Res 2023; 25:e41490. [PMID: 37255277 PMCID: PMC10365576 DOI: 10.2196/41490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 11/30/2022] [Accepted: 02/28/2023] [Indexed: 03/06/2023] Open
Abstract
BACKGROUND A written action plan (WAP) for managing asthma exacerbations is recommended. OBJECTIVE We aimed to compare the effect on unscheduled medical contacts (UMCs) of a digital action plan (DAP) accessed via a smartphone web app combined with a WAP on paper versus that of the same WAP alone. METHODS This randomized, unblinded, multicenter (offline recruitment in private offices and public hospitals), and parallel-group trial included children (aged 6-12 years) or adults (aged 18-60 years) with asthma who had experienced at least 1 severe exacerbation in the previous year. They were randomized to a WAP or DAP+WAP group in a 1:1 ratio. The DAP (fully automated) provided treatment advice according to the severity and previous pharmacotherapy of the exacerbation. The DAP was an algorithm that recorded 3 to 9 clinical descriptors. In the app, the participant first assessed the severity of their current symptoms on a 10-point scale and then entered the symptom descriptors. Before the trial, the wordings and ordering of these descriptors were validated by 50 parents of children with asthma and 50 adults with asthma; the app was not modified during the trial. Participants were interviewed at 3, 6, 9, and 12 months to record exacerbations, UMCs, and WAP and DAP use, including the subjective evaluation (availability and usefulness) of the action plans, by a research nurse. RESULTS Overall, 280 participants were randomized, of whom 33 (11.8%) were excluded because of the absence of follow-up data after randomization, leaving 247 (88.2%) participants (children: n=93, 37.7%; adults: n=154, 62.3%). The WAP group had 49.8% (123/247) of participants (children: n=45, 36.6%; mean age 8.3, SD 2.0 years; adults: n=78, 63.4%; mean age 36.3, SD 12.7 years), and the DAP+WAP group had 50.2% (124/247) of participants (children: n=48, 38.7%; mean age 9.0, SD 1.9 years; adults: n=76, 61.3%; mean age 34.5, SD 11.3 years). Overall, the annual severe exacerbation rate was 0.53 and not different between the 2 groups of participants. The mean number of UMCs per year was 0.31 (SD 0.62) in the WAP group and 0.37 (SD 0.82) in the DAP+WAP group (mean difference 0.06, 95% CI -0.12 to 0.24; P=.82). Use per patient with at least 1 moderate or severe exacerbation was higher for the WAP (33/65, 51% vs 15/63, 24% for the DAP; P=.002). Thus, participants were more likely to use the WAP than the DAP despite the nonsignificant difference between the action plans in the subjective evaluation. Median symptom severity of the self-evaluated exacerbation was 4 out of 10 and not significantly different from the symptom severity assessed by the app. CONCLUSIONS The DAP was used less often than the WAP and did not decrease the number of UMCs compared with the WAP alone. TRIAL REGISTRATION ClinicalTrials.gov NCT02869958; https://clinicaltrials.gov/ct2/show/NCT02869958.
Collapse
Affiliation(s)
- Nicole Beydon
- Unité Fonctionnelle de Physiologie-Explorations Fonctionnelles Respiratoires, Institut National de la Santé et de la Recherche Médicale 938, Centre de Recherche Saint Antoine, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris, F-75012, Paris, France
| | - Camille Taillé
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale 1152, Université Paris Cité, F-75018, Paris, France
| | - Harriet Corvol
- Service de Pneumologie Pédiatrique, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale Centre de Recherche Saint-Antoine, Sorbonne Université, F-75012, Paris, France
| | - Judith Valcke
- Service de Pneumologie, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, F-75015 Paris, Hôpital Privé Armand Brillard, F-94130, Paris, France
| | - Jean-Jacques Portal
- Clinical Research Unit Saint-Louis Lariboisière, Assistance Publique Hôpitaux de Paris, Université de Paris Cité, F-75010, Paris, France
| | - Laurent Plantier
- Département de Pneumologie et Explorations Fonctionnelles Respiratoires, Centre Hospitalier Universitaire de Tours, Institut National de la Santé et de la Recherche Médicale unité 1100, Université de Tours, F-37000, Tours, France
| | - Gilles Mangiapan
- Service de Pneumologie, Centre Hospitalier Interrégional de Créteil, F-94010, Créteil, France
| | - Caroline Perisson
- Service de Pneumologie Pédiatrique, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale Centre de Recherche Saint-Antoine, Sorbonne Université, F-75012, Paris, France
| | - Guillaume Aubertin
- Centre de pneumologie et d'allergologie de l'enfant, F-92100, Boulogne Billancourt, France
| | - Alice Hadchouel
- Service de Pneumologie Pédiatrique, Centre de Référence pour les Maladies Respiratoires Rares de l'Enfant, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université de Paris Cité, F-75015, Paris, France
| | - Guillaume Briend
- Service de Pneumologie, Centre hospitalier de Pontoise, F-95303, Cergy Pontoise, France
| | - Laurent Guilleminault
- Département de Pneumologie et Allergologie, Centre Hospitalo-Universitaire Purpan, Centre National de la Recherche Scientifique U5282, Institut National de la Santé et de la Recherche Médicale U1291, Toulouse Institute for Infectious, Inflammatory Disease, Toulouse, France
| | - Catherine Neukirch
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique des Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale 1152, F-75018, Paris, France
| | - Pierrick Cros
- Département de Pédiatrie, Hôpital Universitaire Morvan, F-29200, Brest, France
| | | | | | - Eric Vicaut
- Clinical Research Unit Saint-Louis Lariboisière, Assistance Publique Hôpitaux de Paris, Université de Paris Cité, F-75010, Paris, France
| | - Christophe Delclaux
- Service de Physiologie Pédiatrique-Centre du Sommeil, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale NeuroDiderot, Université de Paris Cité, F-75019, Paris, France
| |
Collapse
|
5
|
Neukirch C, Thibaut de Menonville C, Laborier F, Elbany C, Van der Brempt X, Nicaise-Roland P. Réactions croisées dans le monde des hyménoptères. Revue Française d'Allergologie 2023. [DOI: 10.1016/j.reval.2023.103305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
6
|
Lam HCY, Neukirch C, Janson C, Garcia-Aymerich J, Clausen M, Idrose NS, Demoly P, Bertelsen RJ, Ruiz LC, Raherison C, Jarvis DL. Food hypersensitivity: an examination of factors influencing symptoms and temporal changes in the prevalence of sensitization in an adult sample. Eur J Clin Nutr 2023:10.1038/s41430-023-01284-w. [PMID: 36964270 PMCID: PMC10393775 DOI: 10.1038/s41430-023-01284-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 03/06/2023] [Accepted: 03/10/2023] [Indexed: 03/26/2023]
Abstract
BACKGROUND/OBJECTIVES Food hypersensitivity (FHS) is common, but little is known about the factors associated with severe reactions, age of onset and whether sensitization persists. This study examines the factors associated with self-reported severe food reactions, onset age and the changes in prevalence of sensitization to foods over time in an adult sample. SUBJECTS/METHODS We used data from adults taking part in the European Community Respiratory Health Survey (ECRHS) III (2010-2014) who provided information on food hypersensitivity, including symptoms, suspected culprit food and onset age (n = 4865). A subsample from six countries had serum food-specific IgE tested for 25 core foods and also in 10 years earlier (ECRHS II). We applied logistic regression and McNemar's test for analyses. RESULTS The prevalence of self-reported FHS was 13.5% at ECRHS III. Of those providing information on symptoms (n = 611), 26.4% reported severe reactions. About 80% of 1033 reported food-specific reactions (reported by 596 participants) began after age 15. History of asthma (odds ratio OR 2.12 95% confidence interval CI 1.13-3.44) and a younger age of onset of FHS (OR 1.02, 95% CI 1.01-1.03, per year) were associated with higher risks of a lifetime experience of severe food reactions. In the subsample with IgE tested in both surveys (n = 1612), the overall prevalence of sensitization to foods did not change over 10 years. CONCLUSION Our findings support previous observations of more severe food reactions in people with asthma and that most FHS reported by this sample started after age 15. We found no evidence of changes in the prevalence of sensitization to food in adults followed for 10 years.
Collapse
Affiliation(s)
- Holly C Y Lam
- National Heart and Lung Institute, Imperial College London, London, UK.
- MRC Centre for Environment and Health, Imperial College London, London, UK.
| | - Catherine Neukirch
- Service de Pneumologie, AP-HP, Hôpital Bichat, Université de Paris, INSERM 1152, F-75018, Paris, France
| | - Christer Janson
- Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
| | - Judith Garcia-Aymerich
- Barcelona Institute of Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - Michael Clausen
- Children's Hospital and Department of Allergy, Landspitali University Hospital, 101, Reykjavik, Iceland
| | - N Sabrina Idrose
- Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia
- Centre for Food and Allergy Research, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia
| | - Pascal Demoly
- Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
| | - Randi J Bertelsen
- Department of Clinical Science, University of Bergen, Bergen, Norway
- Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway
| | - Lidia C Ruiz
- Social Epidemiology and Health Policy (SEHPO), Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
| | - Chantal Raherison
- University of Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France
| | - Deborah L Jarvis
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC Centre for Environment and Health, Imperial College London, London, UK
| |
Collapse
|
7
|
Lecolant S, Khelifi D, Neukirch C, Taillé C, Chabane H, Giboury Lafarge S, Sève E, Pham Thi N, Epstein M, Chollet Martin S, Nicaise Roland P. Comparaison des performances diagnostiques de deux biopuces IgE : ISAC® et ALEX2®. Revue Française d'Allergologie 2023. [DOI: 10.1016/j.reval.2023.103289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
8
|
Pouessel G, Tanno L, Beaudouin E, Chatain C, Corriger J, Demoly P, Flabbée J, Jacquier J, Larroche Y, Neukirch C, Leroy S, Mariotte D, le Mauff B, Mertes P, Thi N, Pouessel G, Tacquard C, Tanno L, Vitte J. Les sapeurs-pompiers en première ligne dans l’anaphylaxie ! Revue Française d'Allergologie 2022. [DOI: 10.1016/j.reval.2022.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Langlois T, Nicaise-Roland P, Taillé C, Natta P, Crestani B, Chollet-Martin S, de Chaisemartin L, Neukirch C. Higher basal tryptase, asthma and loss of consciousness in anaphylaxis are associated with biphasic reactions. Clin Transl Allergy 2022; 12:e12166. [PMID: 35734270 PMCID: PMC9198564 DOI: 10.1002/clt2.12166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Terence Langlois
- Service de pneumologie A APHP Hôpital Bichat Paris France.,Université Paris-Saclay Paris France
| | - Pascale Nicaise-Roland
- Service d'Immunologie APHP Hôpital Bichat Paris France.,Université de Paris Cité Inserm 1152 Paris France
| | - Camille Taillé
- Service de pneumologie A APHP Hôpital Bichat Paris France.,Université de Paris Cité Inserm 1152 Paris France
| | - Patrick Natta
- Service de pneumologie A APHP Hôpital Bichat Paris France
| | - Bruno Crestani
- Service de pneumologie A APHP Hôpital Bichat Paris France.,Université de Paris Cité Inserm 1152 Paris France
| | - Sylvie Chollet-Martin
- Service d'Immunologie APHP Hôpital Bichat Paris France.,Université Paris-Saclay Inserm Inflammation Microbiome et Immunosurveillance Châtenay-Malabry France
| | - Luc de Chaisemartin
- Service d'Immunologie APHP Hôpital Bichat Paris France.,Université Paris-Saclay Inserm Inflammation Microbiome et Immunosurveillance Châtenay-Malabry France
| | - Catherine Neukirch
- Service de pneumologie A APHP Hôpital Bichat Paris France.,Université de Paris Cité Inserm 1152 Paris France
| |
Collapse
|
10
|
Gouel-Cheron A, Neukirch C, Kantor E, Malinovsky JM, Tacquard C, Montravers P, Mertes PM, Longrois D. Clinical reasoning in anaphylactic shock: addressing the challenges faced by anaesthesiologists in real time: A clinical review and management algorithms. Eur J Anaesthesiol 2021; 38:1158-1167. [PMID: 33973926 DOI: 10.1097/eja.0000000000001536] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Acute hypersensitivity reactions to drugs occur infrequently during anaesthesia and the peri-operative period. When clinical presentation includes the classical triad, erythema, cardiovascular abnormalities and increased airway pressure, the diagnosis is evident and the challenge is to prescribe a therapeutic regimen according to guidelines and to manage refractory signs in a timely manner. In many situations, however, the initial clinical signs are isolated, such as increased airway pressure or arterial hypotension. Rendering a differential diagnosis with causes and mechanisms other than acute hypersensitivity reactions (AHRs) is difficult, delaying treatment with possible worsening of the clinical signs, and even death, in previously healthy individuals. In these difficult diagnostic situations, clinical reasoning is mandatory, and guidelines do not explicitly explain the elements on which clinical reasoning can be built. In this article, based on clinical evidence whenever available, experimental data and pathophysiology, we propose algorithms that have been evaluated by experts. The goal of these algorithms is to provide explicit elements on which the differential diagnosis of AHRs can be made, accelerating the implementation of adequate therapy.
Collapse
Affiliation(s)
- Aurelie Gouel-Cheron
- From the Anaesthesiology and Critical Care Medicine Department, DMU PARABOL, Bichat Hospital, AP-HP (AGC, EK, PM, DL), Antibody in Therapy and Pathology, Pasteur Institute, UMR 1222 INSERM, Paris, France (AGC), Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (AGC), Pulmonology Department, Bichat Hospital, AP-HP, Paris University (CN), INSERM UMR 1152, Paris University, DHU FIRE, Paris (CN, PM), Anaesthesiology and Critical Care Medicine Department, Maison Blanche Hospital, Centre Hospitalier Universitaire de Reims, Reims (JM-M), Anaesthesiology and Critical Care Medicine Department, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg (CT, PM-M), Paris University (PM, DL), EA 3072, Institut de Physiologie, FMTS, Faculté de Médecine de Strasbourg, Université de Strasbourg, Strasbourg (PM-M) and INSERM1148, Paris, France (DL)
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Ghanem M, Homps-Legrand M, Garnier M, Morer L, Goletto T, Frija-Masson J, Wicky PH, Jaquet P, Bancal C, Hurtado-Nedelec M, de Chaisemartin L, Jaillet M, Mailleux A, Quesnel C, Poté N, Debray MP, de Montmollin E, Neukirch C, Borie R, Taillé C, Crestani B. Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia. Am J Physiol Lung Cell Mol Physiol 2021; 321:L847-L858. [PMID: 34496650 PMCID: PMC8562948 DOI: 10.1152/ajplung.00105.2021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Increased blood fibrocytes are associated with a poor prognosis in fibrotic lung diseases. We aimed to determine whether the percentage of circulating fibrocytes could be predictive of severity and prognosis during coronavirus disease 2019 (COVID-19) pneumonia. Blood fibrocytes were quantified by flow cytometry as CD45+/CD15-/CD34+/collagen-1+ cells in patients hospitalized for COVID-19 pneumonia. In a subgroup of patients admitted in an intensive care unit (ICU), fibrocytes were quantified in blood and bronchoalveolar lavage (BAL). Serum amyloid P (SAP), transforming growth factor-β1 (TGF-β1), CXCL12, CCL2, and FGF2 concentrations were measured. We included 57 patients in the hospitalized group (median age = 59 yr [23-87]) and 16 individuals as healthy controls. The median percentage of circulating fibrocytes was higher in the patients compared with the controls (3.6% [0.2-9.2] vs. 2.1% [0.9-5.1], P = 0.04). Blood fibrocyte count was lower in the six patients who died compared with the survivors (1.6% [0.2-4.4] vs. 3.7% [0.6-9.2], P = 0.02). Initial fibrocyte count was higher in patients showing a complete lung computed tomography (CT) resolution at 3 mo. Circulating fibrocyte count was decreased in the ICU group (0.8% [0.1-2.0]), whereas BAL fibrocyte count was 6.7% (2.2-15.4). Serum SAP and TGF-β1 concentrations were increased in hospitalized patients. SAP was also increased in ICU patients. CXCL12 and CCL2 were increased in ICU patients and negatively correlated with circulating fibrocyte count. We conclude that circulating fibrocytes were increased in patients hospitalized for COVID-19 pneumonia, and a lower fibrocyte count was associated with an increased risk of death and a slower resolution of lung CT opacities.
Collapse
Affiliation(s)
- Mada Ghanem
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Méline Homps-Legrand
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Marc Garnier
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,Sorbonne Université, APHP, DMU DREAM, Service d'Anesthésie-Réanimation et Médecine Périopératoire, Hôpital Tenon, Paris, France
| | - Lise Morer
- APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Tiphaine Goletto
- APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | | | - Paul-Henri Wicky
- APHP, Service de Réanimation Médicale et Infectieuse, Hôpital Bichat, Paris, France
| | - Pierre Jaquet
- APHP, Service de Réanimation Médicale et Infectieuse, Hôpital Bichat, Paris, France
| | - Catherine Bancal
- APHP, Laboratoire d'Explorations Fonctionnelles, Hôpital Bichat, Paris, France
| | | | - Luc de Chaisemartin
- Université Paris-Sud, Université Paris-Saclay, APHP, Laboratoire d'immunologie, Hôpital Bichat, Paris, France, Inserm, Châtenay-Malabry, France
| | - Madeleine Jaillet
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Arnaud Mailleux
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France
| | - Christophe Quesnel
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,Sorbonne Université, APHP, DMU DREAM, Service d'Anesthésie-Réanimation et Médecine Périopératoire, Hôpital Tenon, Paris, France
| | - Nicolas Poté
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service d'Anatomie et Cytologie pathologique, Hôpital Bichat, Paris, France
| | - Marie-Pierre Debray
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Radiologie, Hôpital Bichat, Paris, France
| | | | - Catherine Neukirch
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Raphael Borie
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Camille Taillé
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | - Bruno Crestani
- Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.,APHP, Service de Pneumologie A, Centre de référence des Maladies Pulmonaires Rares, FHU APOLLO, Hôpital Bichat, Paris, France
| | | |
Collapse
|
12
|
Caimmi D, Neukirch C, Demoly P. Essential oils: what is the clinical tolerance in asthmatic patients? J Asthma 2021; 59:934-936. [PMID: 33577354 DOI: 10.1080/02770903.2021.1888975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Essential oils in air-spray form are being more and more used for several purposes, even by allergic and asthmatic patients. Available data on the potentially dangerous effects of volatile organic compounds and terpenes contained in essential oils are scarce, and sometimes difficult to compare. Through the present work, we evaluated the clinical tolerance of asthmatic patients exposed to compounds emitted by an essential oils spray, and compared previous and new data available in the scientific literature, focusing on the aspects that may influence clinical results.
Collapse
Affiliation(s)
- D Caimmi
- Allergy Unit, Department of Pulmonology, CHU de Montpellier, Montpellier, France.,IDESP, UMR Inserm, Université de Montpellier, Montpellier, France
| | - C Neukirch
- Service de Pneumologie A, Hôpital Bichat-Claude Bernard, Paris, France.,Inserm U 1152, Faculté de Médecine Paris Diderot, Paris, France
| | - P Demoly
- Allergy Unit, Department of Pulmonology, CHU de Montpellier, Montpellier, France.,IDESP, UMR Inserm, Université de Montpellier, Montpellier, France
| |
Collapse
|
13
|
Borie R, Savale L, Dossier A, Ghosn J, Taillé C, Visseaux B, Jebreen K, Diallo A, Tesmoingt C, Morer L, Goletto T, Faucher N, Hajouji L, Neukirch C, Phillips M, Stelianides S, Bouadma L, Brosseau S, Ottaviani S, Pluvy J, Le Pluart D, Debray MP, Raynaud-Simon A, Descamps D, Khalil A, Timsit JF, Lescure FX, Descamps V, Papo T, Humbert M, Crestani B, Dieude P, Vicaut E, Zalcman G. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS One 2020; 15:e0243961. [PMID: 33326457 PMCID: PMC7743937 DOI: 10.1371/journal.pone.0243961] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 12/02/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. MATERIAL AND METHODS A cohort study was designed to evaluate whether a therapeutic algorithm using steroids with or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients with a ≥5-day evolution since symptoms onset, with hyper-inflammation (CRP≥50mg/L), requiring 3-5 L/min oxygen, received methylprednisolone alone. Patients needing ≥6 L/min received methylprednisolone + subcutaneous anakinra daily either frontline or in case clinical deterioration upon corticosteroids alone. Death rate and death or intensive care unit (ICU) invasive ventilation rate at Day 15, with Odds Ratio (OR) and 95% CIs, were determined according to logistic regression and propensity scores. A Bayesian analysis estimated the treatment effects. RESULTS Of 108 consecutive patients, 70 patients received glucocorticoids alone. The control group comprised 63 patients receiving standard of care. In the corticosteroid±stanakinra group (n = 108), death rate was 20.4%, versus 30.2% in the controls, indicating a 30% relative decrease in death risk and a number of 10 patients to treat to avoid a death (p = 0.15). Using propensity scores a per-protocol analysis showed an OR for COVID-19-related death of 0.9 (95%CI [0.80-1.01], p = 0.067). On Bayesian analysis, the posterior probability of any mortality benefit with corticosteroids+/-anakinra was 87.5%, with a 7.8% probability of treatment-related harm. Pre-existing diabetes exacerbation occurred in 29 of 108 patients (26.9%). CONCLUSION In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.
Collapse
Affiliation(s)
- Raphael Borie
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Laurent Savale
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Antoine Dossier
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jade Ghosn
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Camille Taillé
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Benoit Visseaux
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Kamel Jebreen
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Abourahmane Diallo
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Chloe Tesmoingt
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lise Morer
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Tiphaine Goletto
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Nathalie Faucher
- Geriatrics Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Linda Hajouji
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Catherine Neukirch
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Mathilde Phillips
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sandrine Stelianides
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Lila Bouadma
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Solenn Brosseau
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Sébastien Ottaviani
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Johan Pluvy
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Le Pluart
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marie-Pierre Debray
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Agathe Raynaud-Simon
- Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Diane Descamps
- Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Antoine Khalil
- Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Jean Francois Timsit
- Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Francois-Xavier Lescure
- Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Vincent Descamps
- Dermatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Thomas Papo
- Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Marc Humbert
- Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France
| | - Bruno Crestani
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Philippe Dieude
- Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | - Eric Vicaut
- Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France
| | - Gérard Zalcman
- Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France
| | | |
Collapse
|
14
|
Caimmi D, Neukirch C, Louis R, Malard O, Thabut G, Demoly P. Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study. Int Arch Allergy Immunol 2020; 182:182-189. [PMID: 32961531 DOI: 10.1159/000510592] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Accepted: 07/29/2020] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION Among allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms. METHODS This prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel® Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed. RESULTS The mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 4.1 (p < 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p < 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 18.5 L/min. CONCLUSION A hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.
Collapse
Affiliation(s)
- Davide Caimmi
- Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France, .,UMR-S 1136 INSERM-Sorbonne Université, Equipe EPAR - IPLESP, Paris, France,
| | - Catherine Neukirch
- Departments of Pneumology A and B and INSERM U1152, Bichat-Claude Bernard University Hospital, Paris, France
| | - Renaud Louis
- Department of Pulmonary Medicine, CHU Sart-Tilman, IGIGA Research Group, University of Liege, Liège, Belgium
| | - Olivier Malard
- Service d'ORL et de Chirurgie Cervico-Faciale, University Hospital of Nantes, Hôtel Dieu, Nantes, France
| | - Gabriel Thabut
- Departments of Pneumology A and B and INSERM U1152, Bichat-Claude Bernard University Hospital, Paris, France
| | - Pascal Demoly
- Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France.,UMR-S 1136 INSERM-Sorbonne Université, Equipe EPAR - IPLESP, Paris, France
| |
Collapse
|
15
|
Granger V, Taillé C, Roach D, Letuvé S, Dupin C, Hamidi F, Noël B, Neukirch C, Aubier M, Pretolani M, Chollet-Martin S, De Chaisemartin L. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma. World Allergy Organ J 2020. [DOI: 10.1016/j.waojou.2020.100386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
16
|
Baillard S, Sahli F, Petit S, Gigant N, Gouel-Chéron A, Noël B, Neukirch C, Bruhns P, Jönsson F, Longrois D, Pallardy M, Joseph D, Chollet-Martin S, De Chaisemartin L. NMBA-specific memory T cell quantification by CD154 expression in anaphylaxis diagnosis. World Allergy Organ J 2020. [DOI: 10.1016/j.waojou.2020.100396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Roland PN, Laugiel M, Lautraite R, Kaci-Chaouche C, Jaballah F, Deva-Nathan A, Le A, Pinard A, De Chaisemartin L, Granger V, Natta P, Chollet-Martin S, Neukirch C. Basophil activation test is a useful tool for Hymenoptera venom immunotherapy follow-up. World Allergy Organ J 2020. [DOI: 10.1016/j.waojou.2020.100354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Granger V, Taillé C, Roach D, Letuvé S, Dupin C, Hamidi F, Noël B, Neukirch C, Aubier M, Pretolani M, Chollet‐Martin S, de Chaisemartin L. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma. Allergy 2020; 75:699-702. [PMID: 31549729 DOI: 10.1111/all.14059] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Vanessa Granger
- Hôpital Bichat UF Auto‐immunité et Hypersensibilités APHP HUPNVS Paris France
- Inflammation Chimiokines et Immunopathologie Faculté de Pharmacie INSERM UMR996 Université Paris‐Sud Université Paris‐Saclay Châtenay‐Malabry France
| | - Camille Taillé
- Hôpital Bichat Service de Pneumologie A APHP HUPNVS Paris France
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Dwayne Roach
- Département de Microbiologie Institut Pasteur Unité de Biologie Moléculaire du gène chez les Extrêmophiles Paris France
| | - Séverine Letuvé
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Clairelyne Dupin
- Hôpital Bichat Service de Pneumologie A APHP HUPNVS Paris France
| | - Fatima Hamidi
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Benoît Noël
- Inflammation Chimiokines et Immunopathologie Faculté de Pharmacie INSERM UMR996 Université Paris‐Sud Université Paris‐Saclay Châtenay‐Malabry France
| | - Catherine Neukirch
- Hôpital Bichat Service de Pneumologie A APHP HUPNVS Paris France
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Michel Aubier
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Marina Pretolani
- Labex Inflamex DHU FIRE INSERM UMR 1152 Université de Paris Paris France
| | - Sylvie Chollet‐Martin
- Hôpital Bichat UF Auto‐immunité et Hypersensibilités APHP HUPNVS Paris France
- Inflammation Chimiokines et Immunopathologie Faculté de Pharmacie INSERM UMR996 Université Paris‐Sud Université Paris‐Saclay Châtenay‐Malabry France
| | - Luc de Chaisemartin
- Hôpital Bichat UF Auto‐immunité et Hypersensibilités APHP HUPNVS Paris France
- Inflammation Chimiokines et Immunopathologie Faculté de Pharmacie INSERM UMR996 Université Paris‐Sud Université Paris‐Saclay Châtenay‐Malabry France
| |
Collapse
|
19
|
Jönsson F, de Chaisemartin L, Granger V, Gouel-Chéron A, Gillis CM, Zhu Q, Dib F, Nicaise-Roland P, Ganneau C, Hurtado-Nedelec M, Paugam-Burtz C, Necib S, Keita-Meyer H, Le Dorze M, Cholley B, Langeron O, Jacob L, Plaud B, Fischler M, Sauvan C, Guinnepain MT, Montravers P, Aubier M, Bay S, Neukirch C, Tubach F, Longrois D, Chollet-Martin S, Bruhns P. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med 2019; 11:11/500/eaat1479. [DOI: 10.1126/scitranslmed.aat1479] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 12/21/2018] [Accepted: 05/21/2019] [Indexed: 12/20/2022]
Abstract
Anaphylaxis is a systemic acute hypersensitivity reaction that is considered to depend on allergen-specific immunoglobulin E (IgE) antibodies and histamine release by mast cells and basophils. Nevertheless, allergen-specific IgG antibodies have been proposed to contribute when the allergen is an abundant circulating large molecule, e.g., after infusions of therapeutic antibodies or dextran. Data from animal models demonstrate a pathway involving platelet-activating factor (PAF) release by monocytes/macrophages and neutrophils activated via their Fc gamma receptors (FcγRs). We hypothesized that such a pathway may also apply to small drugs and could be responsible for non–IgE-mediated anaphylaxis and influence anaphylaxis severity in humans. We prospectively conducted a multicentric study of 86 patients with suspected anaphylaxis to neuromuscular-blocking agents (NMBAs) during general anesthesia and 86 matched controls. We found that concentrations of anti-NMBA IgG and markers of FcγR activation, PAF release, and neutrophil activation correlated with anaphylaxis severity. Neutrophils underwent degranulation and NETosis early after anaphylaxis onset, and plasma-purified anti-NMBA IgG triggered neutrophil activation ex vivo in the presence of NMBA. Neutrophil activation could also be observed in patients lacking evidence of classical IgE-dependent anaphylaxis. This study supports the existence of an IgG-neutrophil pathway in human NMBA-induced anaphylaxis, which may aggravate anaphylaxis in combination with the IgE pathway or underlie anaphylaxis in the absence of specific IgE. These results reconcile clinical and experimental data on the role of antibody classes in anaphylaxis and could inform diagnostic approaches to NMBA-induced acute hypersensitivity reactions.
Collapse
|
20
|
Lejeune S, Deschildre A, Beaudouin E, Labreuche J, Meininger C, Lefort H, Mauriaucourt P, Ganansia O, Wiel E, Pouessel G, Birnbaum J, Charles Bonneau J, Charpin D, Codreanu F, Dona M, Flabbee J, Larroche Y, Lemauff B, Leroy S, Mariotte D, Moneret‐Vautrin D, Michel Mertes P, Morisset N, Neukirch C, Pham‐Thi N, Tazi‐Daoudi L. Pre‐hospital management of paediatric anaphylaxis by French Emergency Medicine physicians: Still to be improved. Clin Exp Allergy 2019; 49:1047-1050. [DOI: 10.1111/cea.13405] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Revised: 03/16/2019] [Accepted: 04/10/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Stéphanie Lejeune
- Pediatric Pulmonology and Allergy Department Pôle Enfant, Hôpital Jeanne de Flandre CHU de Lille and Université Nord de France Lille France
| | - Antoine Deschildre
- Pediatric Pulmonology and Allergy Department Pôle Enfant, Hôpital Jeanne de Flandre CHU de Lille and Université Nord de France Lille France
- Allergy Vigilance Network Vandoeuvre les Nancy France
| | - Etienne Beaudouin
- Allergy Vigilance Network Vandoeuvre les Nancy France
- Institute of Allergology Regional Hospital Center of Metz‐Thionville Metz Cedex France
| | | | | | - Hugues Lefort
- Department of emergency medicine Hôpital d'Instruction des Armées Legouest Metz France
| | - Patrick Mauriaucourt
- Department of emergency medicine Pôle Urgences, Hôpital Roger Salengro CHU de Lille and Université Nord de France Lille France
| | - Olivier Ganansia
- Department of emergency medicine Groupe Hospitalier Paris Saint Joseph Paris France
| | - Eric Wiel
- Department of emergency medicine Pôle Urgences, Hôpital Roger Salengro CHU de Lille and Université Nord de France Lille France
| | - Guillaume Pouessel
- Pediatric Pulmonology and Allergy Department Pôle Enfant, Hôpital Jeanne de Flandre CHU de Lille and Université Nord de France Lille France
- Allergy Vigilance Network Vandoeuvre les Nancy France
- Department of Pediatrics Children's Hospital Roubaix France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Beuraud C, Lombardi V, Luce S, Horiot S, Naline E, Neukirch C, Airouche S, Perchet T, Golub R, Devillier P, Chollet‐Martin S, Baron‐Bodo V, Nony E, Aubier M, Mascarell L, Moingeon P. CCR10 + ILC2s with ILC1-like properties exhibit a protective function in severe allergic asthma. Allergy 2019; 74:933-943. [PMID: 30475388 DOI: 10.1111/all.13679] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 03/09/2018] [Accepted: 09/11/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND We previously showed that patients with severe allergic asthma have high numbers of circulating ILC2s expressing CCR10. METHOD Herein, CCR10+ ILC2s were further analyzed in the blood of healthy individuals or patients with allergic and non-allergic asthma. Characteristics of human CCR10+ and CCR10- ILC2s were assessed by flow cytometry as well as single-cell multiplex RT-qPCR. The role of CCR10+ ILC2s in asthma pathophysiology was studied in allergen-treated mice. RESULTS When compared to healthy controls, CCR10+ ILC2s are enriched in the blood of both allergic and non-allergic severe asthmatic patients, and these cells are recruited to the lungs. Plasma concentrations of the CCR10 ligand CCL27 are significantly increased in severe asthmatics when compared to non-asthmatic patients. CCR10+ ILC2s secrete little TH 2 cytokines, but exhibit ILC1-like properties, including a capacity to produce IFN-γ. Also, single-cell analysis reveals that the CCR10+ ILC2 subset is enriched in cells expressing amphiregulin. CCR10+ ILC2 depletion, as well as blocking of IFN-γ activity, exacerbates airway hyperreactivity in allergen-challenged mice, providing evidence for a protective role of these cells in allergic inflammation. CONCLUSIONS Frequencies of circulating CCR10+ ILC2s and CCL27 plasma concentrations represent candidate markers of asthma severity. The characterization of CCR10+ ILC2s in human samples and in mouse asthma models suggests that these cells downregulate allergic inflammation through IFN-γ production.
Collapse
Affiliation(s)
- Chloé Beuraud
- Research Department Stallergenes Greer Antony France
| | | | - Sonia Luce
- Research Department Stallergenes Greer Antony France
| | | | - Emmanuel Naline
- UPRES EA 220 Airway Disease Department Foch Hospital University Paris‐Saclay Suresnes France
| | - Catherine Neukirch
- Department of Pulmonary Medicine Bichat Hospital Faculty of Medicine Paris Diderot University INSERM UMR1152 Paris France
| | - Sabi Airouche
- Research Department Stallergenes Greer Antony France
| | - Thibaut Perchet
- Unit for Lymphopoiesis Immunology Department INSERM U1223 Institut Pasteur Paris France
| | - Rachel Golub
- Unit for Lymphopoiesis Immunology Department INSERM U1223 Institut Pasteur Paris France
| | - Philippe Devillier
- UPRES EA 220 Airway Disease Department Foch Hospital University Paris‐Saclay Suresnes France
| | | | | | - Emmanuel Nony
- Research Department Stallergenes Greer Antony France
| | - Michel Aubier
- Department of Pulmonary Medicine Bichat Hospital Faculty of Medicine Paris Diderot University INSERM UMR1152 Paris France
| | | | | |
Collapse
|
22
|
Leynaert B, Le Moual N, Neukirch C, Siroux V, Varraso R. [Environmental risk factors for asthma developement]. Presse Med 2019; 48:262-273. [PMID: 30910274 DOI: 10.1016/j.lpm.2019.02.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Revised: 02/12/2019] [Accepted: 02/13/2019] [Indexed: 12/20/2022] Open
Abstract
The prevalence of asthma has increased rapidly since the early 1970s, and only changes in exposure to environmental factors; which go together with changes in lifestyle, are likely to explain such a rapid increase. Exposure to allergens is a risk factor for allergic sensitization, and allergic sensitization is a risk factor for allergic asthma. However, apart from indoor mold exposure as a risk factor for childhood asthma, there is insufficient evidence to conclude that the associations between allergen exposure and asthma development are causal. A new challenge for research is to analyze the huge amount of data derived from the metagenomic characterization of the environmental and human microbiome, to understand the role of interactions between viruses, bacteria and allergens in the development of asthma. It is recognized that prenatal and postnatal exposure to air pollution and maternal smoking increase the risk of developing asthma in children. In adults, the data are scarce and the results remain controversial as regards these exposures and asthma incidence. Further research is needed to appraise the effect of exposure to phenols, phthalates and perfluorinated compounds, which are widespread in the environment and may be associated with asthma, especially in children. Frequent use of chemicals for home cleaning especially in the form of sprays - which is a common practice at the population level - is a risk factor for the development of adult asthma. The domestic use of cleaning products might also be a risk factor for asthma in children exposed at home. The chemicals involved in these relationships are still to be identified. Occupational asthma is a major phenotype of adult asthma. A significant part of these asthma cases might relate to occupational exposure to cleaning products. While there is evidence of associations between diet during pregnancy or during childhood and the risk of developing asthma in children, the data in adults are insufficient. Beyond genetic factors, body composition is influenced by dietary choices and physical activity. Further research is needed to clarify the complex interplay between these nutritional factors and asthma development. The new challenge for research is to decipher the role of all the environmental factors to which the individual is exposed since conception ("exposome") in the development of asthma, using a holistic approach.
Collapse
Affiliation(s)
- Bénédicte Leynaert
- UMR 1152 physiopathologie et épidémiologie des maladies respiratoires, équipe épidémiologie, Inserm, Paris, France; UMR 1152, université Paris Diderot, Paris, France.
| | - Nicole Le Moual
- Inserm U1168, VIMA (aging and chronic diseases, epidemiological and public health approaches), Villejuif, France; UVSQ, UMR-S 1168, université Versailles, Saint-Quentin-en-Yvelines, France
| | - Catherine Neukirch
- UMR 1152 physiopathologie et épidémiologie des maladies respiratoires, équipe épidémiologie, Inserm, Paris, France; UMR 1152, université Paris Diderot, Paris, France; Service de pneumologie A, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, France; DHU FIRE, Paris, France
| | - Valérie Siroux
- Équipe épidémiologie environnement appliquée à la reproduction et la santé respiratoire, Inserm, CNRS, centre de recherche Inserm U1209, institute for advanced biosciences (IAB), université Grenoble-Alpes, Grenoble, France
| | - Raphaëlle Varraso
- Inserm U1168, VIMA (aging and chronic diseases, epidemiological and public health approaches), Villejuif, France; UVSQ, UMR-S 1168, université Versailles, Saint-Quentin-en-Yvelines, France
| |
Collapse
|
23
|
Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse MG, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N, Steg PG. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. Eur Heart J Cardiovasc Pharmacother 2018; 3:77-81. [PMID: 27533953 DOI: 10.1093/ehjcvp/pvw018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 07/26/2016] [Indexed: 11/14/2022]
Abstract
Aims To determine antiplatelet efficacy after desensitization in patients with a history of aspirin hypersensitivity. Methods and results We conducted a case-control study to evaluate the efficacy of aspirin 1 day (D1) and 6-8 weeks (W6-8) after desensitization. We also assessed ex vivo basophil reactivity to aspirin after desensitization. Cases were patients with coronary artery disease (CAD) and documented history of aspirin hypersensitivity who underwent rapid successful oral desensitization to aspirin. Controls were patients with stable CAD without hypersensitivity and receiving aspirin. Among 56 cases, 27 received aspirin for acute coronary syndromes and 29 were treated for stable CAD. Aspirin was effective (defined as light transmission aggregometry induced by arachidonic acid ≤20%) at D1 in 86% of cases (P = 0.045 vs. controls) and in 95% at W6-8, vs. 100% of controls (P = 0.39). Urinary excretion of thromboxane B2 diminished substantially in cases (P < 0.0001, D0 vs. W6-8) but remained higher than in controls (P = 0.03). Platelet reactivity (defined by platelet P-selectin expression, activated glycoprotein IIb/IIIa inhibitors, and platelet-monocyte aggregates) was similar in cases between D0 and D1 but decreased at W6-8. Basophil activation (quantified by upregulation of CD203c in response to aspirin) was higher in cases at W6-8 than in controls (P = 0.0002). Conclusion Thus, following rapid desensitization, aspirin achieves rapid biological efficacy, which is slightly lower at D1, but becomes indistinguishable from chronically treated patients at W6-8. Persistent basophil activation several weeks after desensitization suggests infraclinical hypersensitivity and the need to continue aspirin to maintain desensitization.
Collapse
Affiliation(s)
- Stéphane Manzo-Silberman
- Département de Cardiologie, Hopital Lariboisière, Paris, France.,INSERM UMR-S 942, Université Paris-Diderot, Sorbonne Paris Cité, Paris, France.,Département Hospitalo-Universitaire FIRE Paris, France
| | - Pascale Nicaise-Roland
- Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Bichat, Unité d'Immunologie, Auto-immunité et Hypersensibilités, Paris, France
| | - Catherine Neukirch
- Département Hospitalo-Universitaire FIRE Paris, France.,Service de Pneumologie Allergologie, Hôpitaux Universitaires Paris Nord Val de Seine, AP-HP Hôpital Bichat, Paris, France.,INSERM UMR 1152, Paris, France
| | - Florence Tubach
- Département Hospitalo-Universitaire FIRE Paris, France.,Département d'épidémiologie et recherche clinique, CIC-EC 1425, AP-HP, Hôpital Bichat, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, UMR 1123 ECEVE, Paris, France.,Département Hospitalo-Universitaire FIRE, INSERM, U1123, CIC-EC 1425, Paris, France
| | - Marie-Geneviève Huisse
- Département Hospitalo-Universitaire FIRE Paris, France.,Département d'Hématologie, Hôpitaux Universitaires Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris France.,Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.,INSERM, U1148, Paris, France
| | - Sylvie Chollet-Martin
- Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Bichat, Unité d'Immunologie, Auto-immunité et Hypersensibilités, Paris, France.,INSERM, UMR 996, UFR de Pharmacie, Université Paris-Sud, Châtenay-Malabry, France
| | - Hélène Abergel
- Département Hospitalo-Universitaire FIRE Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.,INSERM, U1148, Paris, France.,FACT (French Alliance for Cardiovascular clinical Trials)
| | - Fathi Driss
- Département Hospitalo-Universitaire FIRE Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.,INSERM, U1148, Paris, France.,Département de Biochimie, Hôpitaux Universitaires Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris France
| | - Toni Alfaiate
- Département d'épidémiologie et recherche clinique, CIC-EC 1425, AP-HP, Hôpital Bichat, Paris, France
| | - Nadine Ajzenberg
- Département Hospitalo-Universitaire FIRE Paris, France.,Département d'Hématologie, Hôpitaux Universitaires Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris France.,Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.,INSERM, U1148, Paris, France
| | - Philippe Gabriel Steg
- Département Hospitalo-Universitaire FIRE Paris, France.,Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.,INSERM, U1148, Paris, France.,FACT (French Alliance for Cardiovascular clinical Trials).,National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK
| |
Collapse
|
24
|
Abstract
Background: Essential oils are volatile compounds of plant origin increasingly used by allergic and/or asthmatic subjects to purify indoor air. The active compounds of essential oils belong to terpenes, the most widespread biogenic volatile organic compounds (VOC). Although there is substantial literature showing associations between exposure to chemical VOCs and asthmatic symptoms and impaired respiratory function, the impact of essential oils in patients with asthma has never been studied. Objectives: To evaluate the safety of a purifying air spray containing 41 essential oils (PPAS) in patients with mild or moderate allergic asthma. Methods: This was a prospective open study in which 25 mild (19) and moderate (6) asthmatics were exposed to PPAS, one spray twice a day at 8 am and 8 pm in two different corners of a given subjects bedroom for 4 weeks. Before and after 4 weeks of exposure, fractional exhaled nitric oxide (FeNO), lung function and methacholine challenge (PD20) were performed and asthma control was assessed by the 5 questions of the Asthma Control Test (ACT). The spray was weighed after the 4-week exposure to assess compliance. Results: FeNO was the primary endpoint and was thus analyzed in all (N = 25) subjects irrespective of the level of airflow obstruction. The results apply to all (N = 25) subjects in which FeNO could be measured at D1 and D30 (17 subjects). Mean (SD) FeNO amounted to 37.4 (16.6) and to 33.1 (18.7) ppm before and after PPAS exposure, respectively (p = 0.09). No significant change in lung function and methacholine responsiveness was noted after PPAS exposure, the mean PD20 amounting to 1179 (1124.42) μg (range 100-3200) before and to 1226 (1189.8) μg (p = 0.06) after. The mean ACT before and after PPAS exposure amounted to 20.9 (4.2) and 21 (5.15), respectively (p = 0.80). The mean weight of the PPAS bottles was 211.4 g (DS:0) before the first use and 171.41 g (DS: 29.8) at the end of the study. The average amount of PPAS used was 40.0 g (29.8). In the subgroup of subjects who used the highest quantities of essential oils (>40 g), as assessed by the mean weight of the bottle at the end of the study, FeNO after 30 days of exposure decreased more than in the entire group: 7.9 ppm vs 4.2 ppm (p = 0.07). Conclusion: No difference was noted on airway inflammation, lung function or asthma control in mild and moderate allergic asthmatics after exposure twice a day for one month, to a spray containing a mixture of 41 essential oils.
Collapse
Affiliation(s)
- Jean Levy
- a Department of Pneumology A, Bichat-Claude Bernard University Hospital , Paris , France.,b Department of Pneumology B, Bichat-Claude Bernard University Hospital , Paris , France
| | - Catherine Neukirch
- a Department of Pneumology A, Bichat-Claude Bernard University Hospital , Paris , France.,b Department of Pneumology B, Bichat-Claude Bernard University Hospital , Paris , France
| | - Isabelle Larfi
- a Department of Pneumology A, Bichat-Claude Bernard University Hospital , Paris , France.,b Department of Pneumology B, Bichat-Claude Bernard University Hospital , Paris , France
| | - Pascal Demoly
- c Department of Pneumology and Allergology, Arnaud de Villeneuve Hospital, University Montpellier, and Sorbonne University, INSERM, IPLESP , Paris , France
| | - Gabriel Thabut
- a Department of Pneumology A, Bichat-Claude Bernard University Hospital , Paris , France.,b Department of Pneumology B, Bichat-Claude Bernard University Hospital , Paris , France.,d Faculty of Medicine, Bichat Campus, Paris Diderot University , Paris , France
| |
Collapse
|
25
|
Levy J, Neukirch C, Poirier I, Demoly P, Thabut G. Tolérance d’un spray à base d’huiles essentielles chez des patients asthmatiques ayant un asthme léger à modéré. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Gouel-Chéron A, de Chaisemartin L, Jönsson F, Nicaise-Roland P, Granger V, Sabahov A, Guinnepain MT, Chollet-Martin S, Bruhns P, Neukirch C, Longrois D. Low end-tidal CO2 as a real-time severity marker of intra-anaesthetic acute hypersensitivity reactions. Br J Anaesth 2017; 119:908-917. [DOI: 10.1093/bja/aex260] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/10/2017] [Indexed: 01/03/2023] Open
|
27
|
Barnig C, Baron-Thurotte A, Barbaud A, Beaudouin E, de Blay F, Bonniaud P, Demoly P, Deschildre A, Didier A, Drouet M, Just J, Lavaud F, Mailhol C, Metz-Favre C, Neukirch C, Petit N, Perotin JM, Ponvert C, Sauvage C, Magnan A, Birnbaum J. Recommandations de la Société Française d’Allergologie. Indications des actes allergologiques en Hôpital de Jour. Revue Française d'Allergologie 2017. [DOI: 10.1016/j.reval.2017.05.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
28
|
Andujar P, Courbon D, Bizard E, Marcos E, Adnot S, Boyer L, Demoly P, Jarvis D, Neukirch C, Pin I, Thabut G, Boczkowski J, Leynaert B. Smoking, telomere length and lung function decline: a longitudinal population-based study. Thorax 2017; 73:283-285. [PMID: 28724638 DOI: 10.1136/thoraxjnl-2017-210294] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 05/01/2017] [Accepted: 05/08/2017] [Indexed: 01/08/2023]
Abstract
Telomere shortening is associated with COPD and impaired lung function in cross-sectional studies, but there is no longitudinal study. We used data from 448 participants recruited as part of the French follow-up of the European Community Respiratory Health Survey. We found no relationship between telomere length at baseline and FEV1 decline after 11 years of follow-up. However, heavy smoking was associated with an accelerated FEV1 decline in individuals with short telomeres, but not in subjects with longer telomeres (p for interaction p=0.08). Our findings suggest that short telomere length in peripheral leucocytes might be a marker for increased susceptibility to the effect of smoking.
Collapse
Affiliation(s)
- Pascal Andujar
- Université Paris Est-Créteil, Faculté de Médecine, Créteil, France.,INSERM, U955, DHU ATV-B, Créteil, France.,CHI Créteil, Service de Pneumologie et Pathologie Professionnelle, Créteil, France
| | - Dominique Courbon
- INSERM, UMR1152, Paris, France.,Université Paris-Diderot, DHU FIRE, Paris, France
| | | | | | - Serge Adnot
- Université Paris Est-Créteil, Faculté de Médecine, Créteil, France.,INSERM, U955, DHU ATV-B, Créteil, France.,CHU Mondor, Créteil, France
| | - Laurent Boyer
- Université Paris Est-Créteil, Faculté de Médecine, Créteil, France.,INSERM, U955, DHU ATV-B, Créteil, France.,CHU Mondor, Créteil, France
| | - Pascal Demoly
- Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.,Inserm, UMR-S 1136, UPMC, Université Paris 06, UMRS 1136, Equipe - EPAR - IPLESP, Sorbonne Universités, Paris, France
| | - Debbie Jarvis
- Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, London.,MRC-PHE Centre for Environment and Health, Imperial College London, London, UK
| | - Catherine Neukirch
- INSERM, UMR1152, Paris, France.,CHU Bichat, Service de Pneumologie A, Paris, France
| | - Isabelle Pin
- Université Grenoble-Alpes, Grenoble, France.,INSERM, U823, Grenoble, France.,CHU Grenoble-Alpes, Service de Pédiatrie, Grenoble, France
| | - Gabriel Thabut
- INSERM, UMR1152, Paris, France.,CHU Bichat, Service de Pneumologie B, Paris, France
| | - Jorge Boczkowski
- Université Paris Est-Créteil, Faculté de Médecine, Créteil, France.,INSERM, U955, DHU ATV-B, Créteil, France.,CHU Mondor, Créteil, France
| | - Bénédicte Leynaert
- INSERM, UMR1152, Paris, France.,Université Paris-Diderot, DHU FIRE, Paris, France
| |
Collapse
|
29
|
Lombardi V, Luce S, Moussu H, Morizur L, Gueguen C, Neukirch C, Chollet-Martin S, Mascarell L, Aubier M, Baron-Bodo V, Moingeon P. Effector and regulatory dendritic cells display distinct patterns of miRNA expression. Immun Inflamm Dis 2017; 5:310-317. [PMID: 28497578 PMCID: PMC5569363 DOI: 10.1002/iid3.165] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 04/03/2017] [Accepted: 04/05/2017] [Indexed: 01/04/2023]
Abstract
Introduction MicroRNAs (miRNAs) contribute to the regulation of dendritic cell (DC) polarization, thereby influencing the balance of adaptive immune responses. Herein, we studied the expression of miRNAs in polarized DCs and analyzed whether expression of these miRNAs could be associated with allergic rhinitis and allergen immunotherapy (AIT) outcome. Method Using specific culture conditions, we differentiated immature human monocyte‐derived DCs into DC1, DC2, and DCreg subsets (supporting the differentiation of TH1, TH2 or regulatory T cells, respectively). Profiling of miRNA expression was performed in these DC subpopulations using microarrays. Levels of miRNAs specific for polarized DCs were then evaluated in a cohort of 58 patients with allergic rhinitis and 25 non‐allergic controls, as well as in samples from 30 subjects treated with sublingual grass pollen tablets or placebo for four months. Results We successfully identified 16 miRNAs differentially regulated between immature DCs, DC1, DC2, and DCreg cells. In allergic rhinoconjunctivitis patients, the expression of two of those miRNAs (miR‐132 and miR‐155), was down‐regulated compared to non‐allergic individuals. However, the levels of these miRNAs were not significantly modified following four months of grass pollen immunotherapy. Conclusions Studying polarized DCs and clinical samples from subjects with or without allergic rhinoconjunctivitis, we demonstrated that the expression of two miRNAs linked to effector DCs (i.e., DC1 and/or DC2 cells), was reduced in the blood of patients with allergic rhinoconjunctivitis. Nevertheless, these miRNAs did not represent relevant biomarkers to predict or follow‐up AIT efficacy.
Collapse
Affiliation(s)
| | - Sonia Luce
- Research Department, Stallergenes Greer, Antony, France
| | - Hélène Moussu
- Research Department, Stallergenes Greer, Antony, France
| | - Lise Morizur
- Research Department, Stallergenes Greer, Antony, France
| | | | - Catherine Neukirch
- Department of Pulmonology, University Hospital Paris Nord Val de Seine, Hospital Bichat AP-HP, INSERM UMR 1152, University Hospital Department FIRE, Paris, France
| | - Sylvie Chollet-Martin
- Department of Immunology, INSERM UMRS996, Bichat Claude Bernard Hospital, Paris, France
| | | | - Michel Aubier
- Department of Pulmonology, University Hospital Paris Nord Val de Seine, Hospital Bichat AP-HP, INSERM UMR 1152, University Hospital Department FIRE, Paris, France
| | | | | |
Collapse
|
30
|
Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse M, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N, Steg G. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30097-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Pouessel G, Deschildre A, Beaudouin E, Birnbaum J, Neukirch C, Meininger C, Leroy S. À qui prescrire un dispositif auto-injectable d’adrénaline ? Position des groupes de travail « Anaphylaxie », « Allergie alimentaire », « Insectes piqueurs » sous l’égide de la Société française d’allergologie. Revue Française d'Allergologie 2016. [DOI: 10.1016/j.reval.2016.06.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Pouessel G, Deschildre A, Beaudouin E, Birnbaum J, Neukirch C, Meininger C, Leroy S. Conditions d’établissement du projet d’accueil individualisé pour l’enfant allergique : position des groupes de travail « anaphylaxie », « allergie alimentaire » et « insectes piqueurs » sous l’égide de la Société française d’allergologie. Revue Française d'Allergologie 2016. [DOI: 10.1016/j.reval.2016.05.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Carr DF, Chung WH, Jenkiins RE, Chaponda M, Nwikue G, Cornejo Castro EM, Antoine DJ, Pirmohamed M, Wuillemin N, Dina D, Eriksson KK, Yerly D, Pavlos R, Mckinnin E, Ostrov D, Peters B, Buus S, Koelle D, Chopra A, Rive C, Redwood A, Restrepo S, Bracey A, Yuan J, Gaudieri S, Carrington M, Haas D, Mallal S, Phillips E, De Boer D, Menheere P, Nieuwhof C, Bons J, Jonsson F, De Chaisemartin L, Granger V, Gillis C, Gouel A, Neukirch C, Dib F, Nicaise PR, Longrois D, Tubach F, Martin S, Bruhns P, Chen KL, Liao SL, Sheen YS, Cho YT, Yang CW, Liau JY, Chu CY, Aguiar R, Lopes A, Fernandes N, Viegas L, Pereira-Barbosa MA, Bünter A, Gupta N, Petkovic TP, Wirth N, Pichler WJ, Hausmann O, Yazicioglu M, Ozdemir PG, Ciplak G, Kaya O, Cooke PJ, Mota I, Gaspar Â, Benito-Garcia F, Chambel M, Morais-Almeida M, Marques L, Alcoceba E, Lara S, Carneiro-Leão L, Botelho C, Dias-Castro E, Cernadas JR, Nicholls K, Lay W, Smith O, Collins C, Unglik G, Spriggs K, Auyeung P, McComish J, Douglass JA, Peter JG, Potter P, Carolino F, De Castro ED, Moreira AS, Abreu C, Gomes E, Cardoso BK, Tomaz E, Correia S, Inácio F, Arnold A, Bear N, Rueter K, Gong G, O’Sullivan M, Muthusamy S, Noble V, Lucas M, Buterleviciute N, Rudzeviciene O, Abreu C, May S, Pongdee T, Park M, Griguola L, Vinikovas A, Kašinskaite S, Kvedariene V, Aktas A, Rahman S, Elbi H, Ozyurt BC, Cavkaytar O, Karaatmaca B, Cetinkaya PG, Esenboga S, Sahiner UM, Sekerel BE, Soyer O, Zubrinich C, Tong B, Patel M, Giles M, O’Hehir R, Puy R, Amaral L, Demir S, Gelincik A, Olgac M, Caskun R, Unal D, Colakoglu B, Buyukozturk S, Matute OV, Bernad A, Gastaminza G, Madamba R, Lacasa C, Goikoetxea MJ, D’Amelio C, Rifón J, Martínez N, Ferrer M, Ribeiro C, Faria E, Frutuoso C, Barros A, Lebre R, Pego A, Bom AT, Ensina LF, Aranda C, Nunes IC, Martins AM, Solé D, Bavbek S, Kendirlinan R, Çerçi P, Tutluer S, Soyyigit S, Sözener ZÇ, Aydin Ö, Gümüsburun R, Almeida M, Sai K, Imatoh T, Nakamura R, Fukazawa C, Hinomura Y, Saito Y, Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Delgado L, Sai K, Okamoto-Uchida Y, Kajinami K, Matsunaga K, Aihara M, Wang CW, Su SC, Hung SI, Ho HC, Yang CH, Paulmann M, Dunant A, Mockenhaupt M, Sekula P, Schumacher M, Kardaun S, Naldi L, Bellón T, Creamer D, Haddad C, Sassolas B, Lebrun-Vignes B, Valeyrie-Allanore L, Roujeau JC, Paulmann M, Kremmler C, Mockenhaupt M, Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH, Takamura N, Yamane Y, Matsukura S, Nakamura K, Watanabe Y, Yamaguchi Y, Kambara T, Ikezawa Z, Aihara M, Hashimoto R, Chew H, Burnett M, Jeschke M, Knezevic B, Ionmhain UN, Barraclough A, Anstey M, Usui T, Meng X, Farrell J, Whitaker P, Watson J, French N, Park K, Naisbitt D, Neves AC, Cadinha S, Moreira A, Da Silva JPM, Drvar DL, Gulin SJ, Hadzavdic SL, Ceovic R, De Francisco AM, De Vicente Jiménez T, Luque AG, David NR, Galván JMM, Darlenski R, Gulin D, Sikic J, Habek JC, Galic E, Specht P, Staab D, Mayer B, Roehmel J, Solovan C, Chiriac A, Djurinec P, Kostovic K, Bradamante M, Almeida JP, Caiado J, Pedro E, Da Silva PC, Barbosa MP, Bogas G, Blanca-López N, Pérez-Alzate D, Doña I, Agúndez JA, García-Martín E, Cornejo-García JA, Mayorga C, Torres MJ, Canto MG, Blanca M, Aksakal S, Sin AZ, Koç ZP, Günsen FD, Ardeniz Ö, Gökmen ENM, Gülbahar O, Kokuludag A, Pérez-Sánchez N, Salas M, Salas M, Gomez F, Barrionuevo E, Andreu I, Miranda MÁ, Didžiokaite G, Gaidej O, Kašinskaite S, Garcimartin MI, Somoza ML, Bojas G, Cornejo-Garcia JA, Perez FJR, Miranda MA, Jerschow E, Pelletier T, Ren Z, Hudes G, Sanak M, Morales E, Schuster V, Spivack SD, Rosenstreich D, Erzen R, Silar M, Bajrovic N, Rijavec M, Zidarn M, Korosec P, Castro E, Al-Ahmad M, Rodriguez T, Azevedo JP, Tavares B, Regateiro F, Todo-Bom A, Miranda PA, De La Cruz Hoyos B, Abuzeid W, Akbar N, Gibber M, Fried M, Han W, Keskin T, Tamayev R, Spivack SD, Rosenstreich D, Jerschow E, Boni E, Russello M, Mauro M, Neto MF, Brosseron L, Malheiro D, Barreira P, Sprigg D, Trevenen M, Seet J, Trubiano J, Smith W, Jeelall Y, Vale S, Loh R, Mclean-Tooke A, Müller S, Amstutz U, Jörg L, Yawalkar N, Krähenbühl S, Leblanc A, Ribeiro L, Vega A, Rivas RG, Alonso A, Beitia JM, Mateo B, Cárdenas R, Garcia-Dominguez JJ, Pavlos R, Strautins K, James I, Mallal S, Redwood A, Aguiar R, Lopes A, Neves A, Do Céu Machado M, Dalgiç CT, Gökmen ENM, Bulut G, Ardeniz FÖ, Gülbahar O, Sin AZ, Hsu SH, Yang CW, Ye YM, Hur GY, Park HS, Kim SH, Ali S, Hollingsworth PN, Mclean-Tooke APC, Chadly Z, Fredj NB, Aouam K, Romdhane HB, Boughattas NA, Chaabane A, Salazar ML, Pola B, Fiandor A, Ramírez E, Ortega JD, Quirce S, Cabañas R, Baynova K, Labella M, Prados M, Ramonaite A, Bajoriuniene I, Sitkauskiene B, Sakalauskas R, Kwon JW, Park S, Silva D, Leão LC, Castro E, Garcimartin M, De La Torre MV, Pérez FJR, Haroun E, Diez GC, Ónodi-Nagy K, Kinyó Á, Kemény L, Bata-Csörgo Z, Pita JS, Fernandes RA, Moura A, Sousa N, Loureiro C, Pfützner W, Marrouche N, Grattan C, Chen YE, Chen CB, Hsiao YP, Garcimartin MI, Ruano FJ. 7th drug hypersensitivity meeting: part one. Clin Transl Allergy 2016. [PMCID: PMC5009634 DOI: 10.1186/s13601-016-0121-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Oral Abstracts O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN Daniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, Mas Chaponda, Gospel Nwikue, Elena M. Cornejo Castro, Daniel J. Antoine, Munir Pirmohamed O2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture? Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel Yerly O3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity Rebecca Pavlos, Elizabeth Mckinnin, David Ostrov, Bjoern Peters, Soren Buus, David Koelle, Abha Chopra, Craig Rive, Alec Redwood, Susana Restrepo, Austin Bracey, Jing Yuan, Silvana Gaudieri, Mary Carrington, David Haas, Simon Mallal, Elizabeth Phillips O4 Do we need to measure total ige for the interpretation of analytical results of ImmunoCAP dnd 3gAllergy specific IgE? Douwe De Boer, Paul Menheere, Chris Nieuwhof, Judith Bons O5 Neutrophil activation in systemic anaphylaxis: results from the multicentric NASA study Friederike Jonsson, Luc De Chaisemartin, Vanessa Granger, Caitlin Gillis, Aurelie Gouel, Catherine Neukirch, Fadia Dib, Pascale Roland Nicaise, Dan Longrois, Florence Tubach, Sylvie Martin, Pierre Bruhns, NASA Study Group O6 Purpuric drug eruptions due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC): a clinic-pathological study of 32 cases Kai-Lung Chen, Shu-Ling Liao, Yi-Shuan Sheen, Yung-Tsu Cho, Che-Wen Yang, Jau-Yu Liau, Chia-Yu Chu Poster presentations: Poster Walk 1—Anaphylaxis (P01–P09) P1 Anaphylactic reactions during anaesthesia and the perioperative period Rita Aguiar, Anabela Lopes, Natália Fernandes, Leonor Viegas, M. A. Pereira-Barbosa P2 Anaphylaxis to chlorhexidine: is there a cross-reactivity to alexidine? Antonia Bünter, Nisha Gupta, Tatjana Pecaric Petkovic, Nicole Wirth, Werner J. Pichler, Oliver Hausmann P3 Cefotaxime-induced severe anaphylaxis in a neonate Mehtap Yazicioglu, Pinar G. Ozdemir, Gokce Ciplak, Ozkan Kaya P4 Clinical features and diagnosis of anaphylaxis resulting from exposure to chlorhexidine Peter John Cooke P5 Drug-induced anaphylaxis: five-year single-center survey Inês Mota, Ângela Gaspar, Filipe Benito-Garcia, Marta Chambel, Mário Morais-Almeida P6 Intraoperative severe anaphylactic reaction due to patent blue v dye Luis Marques, Eva Alcoceba, Silvia Lara P7 Kounis syndrome in the setting of anaphylaxis to diclofenac Leonor Carneiro-Leão, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P8 Perioperative anaphylaxis audit: Royal Melbourne Hospital Katherine Nicholls, William Lay, Olivia Smith, Christine Collins, Gary Unglik, Kymble Spriggs, Priscilla Auyeung, Jeremy McComish, Jo A. Douglass P9 Recurrent peri-operative anaphylaxis: a perfect storm Jonny G. Peter, Paul Potter Poster Walk 2: DH regions and patient groups (P10–P19) P10 A rare presentation of amoxicillin allergy in a young child Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas P11 Adverse drug reactions in children: antibiotics or virus? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P12 Allergic reactions in invasive medical procedures Bárbara Kong Cardoso, Elza Tomaz, Sara Correia, Filipe Inácio P13 Antibiotic allergy in children: room for improvement Annabelle Arnold, Natasha Bear, Kristina Rueter, Grace Gong, Michael O’Sullivan, Saravanan Muthusamy, Valerie Noble, Michaela Lucas P14 Drug hypersensitivity reactions in children and results of diagnostic evaluation Neringa Buterleviciute, Odilija Rudzeviciene P15 Nonimmediate cutaneous drug reactions in children: are skin tests required? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P16 Pediatric patients with a history of penicillin allergy and a positive penicillin skin test may not be at an increased risk for multiple drug allergies Sara May, Thanai Pongdee, Miguel Park P17 Proved hypersensitivity to drugs according data of Vilnius University Hospital Santariskiu Klinikos Linas Griguola, Arturas Vinikovas, Simona Kašinskaite, Violeta Kvedariene P18 Self-reported prevalence of drug hypersensitivity reactions among students in Celal Bayar University, Turkey Ayse Aktas, Suheyla Rahman, Huseyin Elbi, Beyhan Cengiz Ozyurt P19 Severe drug hypersensitivity reactions in pediatric age Ozlem Cavkaytar, Betul Karaatmaca, Pinar Gur Cetinkaya, Saliha Esenboga, Umit M. Sahiner, Bulent E. Sekerel, Ozge Soyer Poster Walk 3: Desensitisation (P20–P28) P20 A protocol for desensitisation to valaciclovir Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, Robert Puy P21 A rare case of desensitization to modafinil Josefina Cernadas, Luís Amaral, Fabrícia Carolino P22 A sixteen-day desensitization protocol in delayed type hypersensitivity reactions to oral drugs Semra Demir, Asli Gelincik, Muge Olgac, Raif Caskun, Derya Unal, Bahauddin Colakoglu, Suna Buyukozturk P23 Desensitization to intravenous etoposide using a 12 and a 13-step protocol. Two cases report Olga Vega Matute, Amalia Bernad, Gabriel Gastaminza, Roselle Madamba, Carlos Lacasa, M. J. Goikoetxea, Carmen D’Amelio, Jose Rifón, Nicolas Martínez, Marta Ferrer P24 Drug desensitisation in oncology: the experience of an immunoallergology department for 5 years Carmelita Ribeiro, Emília Faria, Cristina Frutuoso, Anabela Barros, Rosário Lebre, Alice Pego, Ana Todo Bom P25 Filgrastim anaphylaxis: a successful desensitization protocol Luis Amaral, Josefina Cernadas P26 Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis VI patient Luis Felipe Ensina, Carolina Aranda, Ines Camelo Nunes, Ana Maria Martins, Dirceu Solé P27 Rapid drug desensitization with biologicals: one-center experience with four biologicals Sevim Bavbek, Resat Kendirlinan, Pamir Çerçi, Seda Tutluer, Sadan Soyyigit, Zeynep Çelebi Sözener, Ömür Aydin, Reyhan Gümüsburun P28 Successful desensitization to a high dose of methotrexate in a delayed type hypersensitivity reaction Josefina Cernadas, Leonor Carneiro-Leão, Fabrícia Carolino, Marta Almeida Poster Walk 4: SJS (P29–P38) P29 Assessment of impact of infection on drug-induced severe cutaneous adverse reactions and rhabdomyolysis using the Japanese adverse drug event report database Kimie Sai, Takuya Imatoh, Ryosuke Nakamura, Chisato Fukazawa, Yasushi Hinomura, Yoshiro Saito P30 Characterization of erythema multiforme and severe cutaneous adverse reactions hospitalizations Bernardo Sousa-Pinto, Cláudia Correia, Lídia Gomes, Sara Gil-Mata, Luís Araújo, Luís Delgado P31 Effects of infection on incidence/severity of SJS/TEN and myopathy in Japanese cases analyzed by voluntary case reports Ryosuke Nakamura, Kimie Sai, Takuya Imatoh, Yoshimi Okamoto-Uchida, Koji Kajinami, Kayoko Matsunaga, Michiko Aihara, Yoshiro Saito P32 Efficacy of tumor necrosis factor—a antagonists in Stevens–Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation Chuang-Wei Wang, Shih-Chi Su, Shuen-Iu Hung, Hsin-Chun Ho, Chih-Hsun Yang, Wen-Hung Chung P33 Evolution of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study Maren Paulmann, Ariane Dunant, Maja Mockenhaupt, Peggy Sekula, Martin Schumacher, Sylvia Kardaun, Luigi Naldi, Teresa Bellón, Daniel Creamer, Cynthia Haddad, Bruno Sassolas, Bénédicte Lebrun-Vignes, Laurence Valeyrie-Allanore, Jean-Claude Roujeau P34 Long-term sequelae in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis Maren Paulmann, Carmen Kremmler, Peggy Sekula, Laurence Valeyrie-Allanore, Luigi Naldi, Sylvia Kardaun, Maja Mockenhaupt P35 Major emotional complications and decreased health related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Anthony Feinstein, Rena Hashimoto, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P36 Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients: treatment and outcome Naoko Takamura, Yumiko Yamane, Setsuko Matsukura, Kazuko Nakamura, Yuko Watanabe, Yukie Yamaguchi, Takeshi Kambara, Zenro Ikezawa, Michiko Aihara P37 Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Rena Hashimoto, Hall Chew, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P38 Stevens–Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report Brittany Knezevic, Una Nic Ionmhain, Allison Barraclough, Michaela Lucas, Matthew Anstey Poster Walk 5: Other organs/unexpected immune reactions (P39–P47) P39 A case report of patient with anti-tuberculosis drug-related severe liver failure Toru Usui, Xiaoli Meng, John Farrell, Paul Whitaker, John Watson, Neil French, Kevin Park, Dean Naisbitt P40 Acute interstitial nephritis induced by ibuprofen Ana Castro Neves, Susana Cadinha, Ana Moreira, J. P. Moreira Da Silva P41 Cetuximab induced acneiform rash—two case reports Daniela Ledic Drvar, Sandra Jerkovic Gulin, Suzana Ljubojevic Hadzavdic, Romana Ceovic P42 Enteropathy associated with losartan Ana Montoro De Francisco, Talía De Vicente Jiménez, Amelia García Luque, Natalia Rosado David, José Mª Mateos Galván P43 Granuloma annulare after therapy with canakinumab Razvigor Darlenski P44 Hypersensitivity eosinophilic myocarditis or acute coronary syndrome? Case report Dario Gulin, Jozica Sikic, Jasna Cerkez Habek, Sandra Jerkovic Gulin, Edvard Galic P45 Piperacillin-induced immune haemolytic anaemia: a severe and frequent complication of antibiotic treatment in patients with cystic fibrosis Philip Specht, Doris Staab, Beate Mayer, Jobst Roehmel P46 Progesterone triggered pemphigus foliaceus: case report Sandra Jerkovic Gulin, Caius Solovan, Anca Chiriac P47 Ramipril: triggered generalized pustular psoriasis Paola Djurinec, Kresimir Kostovic, Mirna Bradamante, Sandra Jerkovic Gulin, Romana Ceovic Poster Walk 6: NSAIDs (P48–P56) P48 Aspirin desensitization in cardiovascular disease—Portuguese experience Jose Pedro Almeida, Joana Caiado, Elisa Pedro, Pedro Canas Da Silva, Manuel Pereira Barbosa P49 Asthma and/or rhinitis to NSAIDs with good tolerance to ASA Gador Bogas, Natalia Blanca-López, Diana Pérez-Alzate, Inmaculada Doña, José Augusto Agúndez, Elena García-Martín, José Antonio Cornejo-García, Cristobalina Mayorga, María José Torres, Gabriela Canto, Miguel Blanca P50 Clinical characteristics of 196 patients with non-steroidal anti-inflammatory drug (NSAIDs) hypersensitivity Sengül Aksakal, Aytül Zerrin Sin, Zeynep Peker Koç, Fatma Düsünür Günsen, Ömür Ardeniz, Emine Nihal Mete Gökmen, Okan Gülbahar, Ali Kokuludag P51 Development of immediate hypersensitivity to several NSAIDs maintaining good tolerance to ASA Natalia Pérez-Sánchez, Natalia Blanca-López, Diana Pérez-Alzate, Gador Bogas, Inmaculada Doña, María Salas, María José Torres, Miguel Blanca, Gabriela Canto P52 Diagnosis of hypersensitivity reactions to paracetamol in a large series of cases Inmaculada Doña, Maria Salas, Francisca Gomez, Natalia Blanca-Lopez, Diana Perez-Alzate, Gador Bogas, Esther Barrionuevo, Maria Jose Torres, Inmaculada Andreu, Miguel Ángel Miranda, Gabriela Canto, Miguel Blanca P53 Hypersensitivity to paracetamol according to the new classification of hypersensitivity to NSAIDs Gabija Didžiokaite, Olesia Gaidej, Simona Kašinskaite, Violeta Kvedariene P54 Ibuprofen and other aryl propionic derivates can induce immediate selective hypersensitivity responses Diana Perez-Alzate, Natalia Blanca-López, Maria Isabel Garcimartin, Inmaculada Doña, Maria Luisa Somoza, Cristobalina Mayorga, Maria Jose Torres, Gador Bojas, Jose Antonio Cornejo-Garcia, Maria Gabriela Canto, Miguel Blanca P55 Subjects developing immediate responses to several NSAIDs can be selective with good tolerance to ASA Natalia Blanca-Lopez, Diana Pérez-Alzate, Francisco Javier Ruano Perez, Inmaculada Doña, Maria Luisa Somoza, Inmaculada Andreu, Miguel Angel Miranda, Cristobalina Mayorga, Maria Jose Torres, Jose Antonio Cornejo-Garcia, Miguel Blanca, Maria Gabriela Canto P56 Utility of low-dose oral aspirin challenges for diagnosis of aspirin exacerbated respiratory disease Elina Jerschow, Teresa Pelletier, Zhen Ren, Golda Hudes, Marek Sanak, Esperanza Morales, Victor Schuster, Simon D. Spivack, David Rosenstreich Poster Walk 7: NSAID 2 (P57–P65) P57 Alternate regulation of cyclooxygenase-2 (COX-2) MRNA expression may predispose patients to aspirin-induced exacerbations Renato Erzen, Mira Silar, Nissera Bajrovic, Matija Rijavec, Mihaela Zidarn, Peter Korosec P58 Anaphylaxis to diclofenac: what about the underlying mechanism? Leonor Carneiro-Leão, Fabrícia Carolino, Luís Amaral, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P59 COX-2 inhibitors: are they always a safe alternative in hypersensitivity to nonsteroidal anti-inflammatory drugs? Luis Amaral, Fabricia Carolino, Eunice Castro, Josefina Cernadas P60 Management of patients with history of NSAIDs reactions prior to coronary angioplasty Mona Al-Ahmad, Tito Rodriguez P61 Oral drug challenge with non-steroidal anti-inflammatory drug under spirometric control: clinical series of 110 patients João Pedro Azevedo, Emília Faria, Beatriz Tavares, Frederico Regateiro, Ana Todo-Bom P62 Prevalence and incidence of analgesic hypersensitivity reactions in Colombia Pablo Andrés Miranda, Bautista De La Cruz Hoyos P63 Recent endoscopic sinus surgery lessens reactions during aspirin challenge in patients with aspirin exacerbated respiratory disease Teresa Pelletier, Waleed Abuzeid, Nadeem Akbar, Marc Gibber, Marvin Fried, Weiguo Han, Taha Keskin, Robert Tamayev, Golda Hudes, Simon D. Spivack, David Rosenstreich, Elina Jerschow P64 Safe use of imidazole salycilate in a case of multiple NSAIDs induced urticaria-angioedema Elisa Boni, Marina Russello, Marina Mauro P65 Selective hypersensitivity reactions to ibuprofen—seven years experience Marta Ferreira Neto Poster Walk 8: Epidemiological methods (P66–P72) P66 Allopurinol hypersensitivity: a 7-year review Lise Brosseron, Daniela Malheiro, Susana Cadinha, Patrícia Barreira, J. P. Moreira Da Silva P67 Antibiotic allergy labelling is associated with increased hospital readmission rates in Australia Brittany Knezevic, Dustin Sprigg, Michelle Trevenen, Jason Seet, Jason Trubiano, William Smith, Yogesh Jeelall, Sandra Vale, Richard Loh, Andrew Mclean-Tooke, Michaela Lucas P68 Experts’ opinions on severe cutaneous adverse drug reactions-report of a survey from the 9th international congress on cutaneous adverse drug reactions 2015 Roni P. Dodiuk-Gad, Cristina Olteanu, Wen-Hung Chung, Neil H. Shear P69 HLA-A*31-positive AGEP with carbamazepine use and other severe cutaneous adverse drug reactions (SCARs) detected by electronic medical records screening Sabine Müller, Ursula Amstutz, Lukas Jörg, Nikhil Yawalkar, Stephan Krähenbühl P70 Patients with suspected drug allergy: a specific psychological profile? Eunice Dias-Castro, Ana Leblanc, Laura Ribeiro, Josefina R. Cernadas P71 Use of an electronic device and a computerized mathematic algorithm to detect the allergic drug reactions through the analysis of heart rate variability Arantza Vega, Raquel Gutierrez Rivas, Ana Alonso, Juan Maria Beitia, Belén Mateo, Remedios Cárdenas, Juan Jesus Garcia-Dominguez P72 Variation in ERAP influences risk for HLA-B*57:01 positive abacavir hypersensitivity Rebecca Pavlos, Kaija Strautins, Ian James, Simon Mallal, Alec Redwood, Elizabeth Phillips Poster Walk 9: DRESS/AGEP (P73–P81) P73 A clinical case of DRESS syndrome in a child after administration of amoxicillin-clavulanic acid Rita Aguiar, Anabela Lopes, Ana Neves, Maria Do Céu Machado, M. A. Pereira-Barbosa P74 Acute generalized exanthematous pustulosis (AGEP) induced by mesalazine, reliable and oftenly used drug to treat inflammatory bowel disease Ceyda Tunakan Dalgiç, Emine Nihal Mete Gökmen, Fatma Düsünür Günsen, Gökten Bulut, Fatma Ömür Ardeniz, Okan Gülbahar, Ali Kokuludag, Aytül Zerrin Sin P75 Changes of blood plasmacytoid dendritic cells, myeloid dendritic cells, and basophils during the acute stage of drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug eruptions Shao-Hsuan Hsu, Yung-Tsu Cho, Che-Wen Yang, Kai-Lung Chen, Chia-Yu Chu P76 Characterization of isoniazid/rifampicin-specific t-cell responses in patients with DRESS syndrome Young-Min Ye, Gyu-Young Hur, Hae-Sim Park, Seung-Hyun Kim P77 DRESS syndrome secondary to sulfasalazine with delayed TEN: a case presentation Syed Ali, Michaela Lucas, Peter N. Hollingsworth, Andrew P. C. Mclean-Tooke P78 Drug rash with eosinophilia and systemic symptoms (DRESS) features according to the culprit drug Zohra Chadly, Nadia Ben Fredj, Karim Aouam, Haifa Ben Romdhane, Naceur A. Boughattas, Amel Chaabane P79 Drug reaction with eosinophilia and systemic symptoms induced by allopurinol: not always easy to diagnose Marina Lluncor Salazar, Beatriz Pola, Ana Fiandor, Teresa Bellón, Elena Ramírez, Javier Domínguez Ortega, Santiago Quirce, Rosario Cabañas P80 Drug reaction with eosinophilia and systemic symptoms syndrome induced by two drugs simultaneously: a case report Krasimira Baynova, Marina Labella, Manuel Prados P81 The drug reaction with eosinophilia and systemic symptoms (DRESS) induced by the second-line antituberculosis drugs and Epstein–Barr virus infection Agne Ramonaite, Ieva Bajoriuniene, Brigita Sitkauskiene, Raimundas Sakalauskas Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91) P82 A case of cycloserine-induced lichenoid drug eruption confirmed with a lymphocatye transformation test Jae-Woo Kwon, Shinyoung Park P83 Allergic reaction to topical eye drops: 5 years’ retrospective study in a drug allergy unit Diana Silva, Leonor Carneiro Leão, Fabricia Carolino, Eunice Castro, Josefina Cernadas P84 Allergy to heparins Diana Perez-Alzate, Natalia Blanca-López, Maria Luisa Somoza Alvarez, Maria Garcimartin, Maria Vazquez De La Torre, Francisco Javier Ruano Pérez, Elisa Haroun, Gabriela Canto Diez P85 Allopurinol-induced adverse drug reactions Katinka Ónodi-Nagy, Ágnes Kinyó, Lajos Kemény, Zsuzsanna Bata-Csörgo P86 Analysis of a population with immediate hypersensitivity to corticosteroids: an 11 year review Joana Sofia Pita, Emília Faria, Rosa Anita Fernandes, Ana Moura, Nuno Sousa, Carmelita Ribeiro, Carlos Loureiro, Ana Todo Bom P87 Anaphylaxis against mivacurium in a 12-months old boy at first-time exposure Wolfgang Pfützner P88 Antihistamine-exacerbated chronic spontaneous urticaria: a paradox? Nadine Marrouche, Clive Grattan P89 Anti-osteoporotic agents-induced cutaneous adverse drug reactions in Asians Yu-En Chen, Chun-Bing Chen, Wen-Hung Chung, Yu-Ping Hsiao, Chia-Yu Chu P90 Diagnosis of allergic reactions to eye drops Maria Vazquez De La Torre, Natalia Blanca-Lopez, Diana Perez-Alzate, Maria Isabel Garcimartin, Francisco Javier Ruano, Maria Luisa Somoza, Elisa Haroun, Gabriela Canto P91 Diagnostic approach in suspected hypersensitivity reactions to corticosteroids Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas
Collapse
|
34
|
Lombardi V, Beuraud C, Neukirch C, Moussu H, Morizur L, Horiot S, Luce S, Wambre E, Linsley P, Chollet-Martin S, Baron-Bodo V, Aubier M, Moingeon P. Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects. J Allergy Clin Immunol 2016; 138:305-308. [PMID: 26949057 DOI: 10.1016/j.jaci.2015.12.1325] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 12/14/2015] [Accepted: 12/28/2015] [Indexed: 02/01/2023]
Affiliation(s)
| | | | | | | | - Lise Morizur
- Research Department, Stallergenes, Antony, France
| | | | - Sonia Luce
- Research Department, Stallergenes, Antony, France
| | - Erik Wambre
- Benaroya Research Institute at Virginia Mason, Seattle, Wash
| | - Peter Linsley
- Benaroya Research Institute at Virginia Mason, Seattle, Wash
| | - Sylvie Chollet-Martin
- Department of Immunology, Bichat-Claude Bernard Hospital, INSERM UMRS996, Paris, France
| | | | - Michel Aubier
- Department of Pulmonary Medicine, INSERM UMR1152, Paris, France
| | | |
Collapse
|
35
|
Amaral AFS, Newson RB, Abramson MJ, Antó JM, Bono R, Corsico AG, de Marco R, Demoly P, Forsberg B, Gislason T, Heinrich J, Huerta I, Janson C, Jõgi R, Kim JL, Maldonado J, Martinez-Moratalla Rovira J, Neukirch C, Nowak D, Pin I, Probst-Hensch N, Raherison-Semjen C, Svanes C, Urrutia Landa I, van Ree R, Versteeg SA, Weyler J, Zock JP, Burney PGJ, Jarvis DL. Changes in IgE sensitization and total IgE levels over 20 years of follow-up. J Allergy Clin Immunol 2015; 137:1788-1795.e9. [PMID: 26586040 PMCID: PMC4889785 DOI: 10.1016/j.jaci.2015.09.037] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 08/21/2015] [Accepted: 09/30/2015] [Indexed: 11/29/2022]
Abstract
Background Cross-sectional studies have reported a lower prevalence of sensitization in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect. Objective We sought to assess changes in sensitization and total IgE levels in a cohort of European adults as they aged over a 20-year period. Methods Levels of serum specific IgE to common aeroallergens (house dust mite, cat, and grass) and total IgE levels were measured in 3206 adults from 25 centers in the European Community Respiratory Health Survey on 3 occasions over 20 years. Changes in sensitization and total IgE levels were analyzed by using regression analysis corrected for potential differences in laboratory equipment and by using inverse sampling probability weights to account for nonresponse. Results Over the 20-year follow-up, the prevalence of sensitization to at least 1 of the 3 allergens decreased from 29.4% to 24.8% (−4.6%; 95% CI, −7.0% to −2.1%). The prevalence of sensitization to house dust mite (−4.3%; 95% CI, −6.0% to −2.6%) and cat (−2.1%; 95% CI, −3.6% to −0.7%) decreased more than sensitization to grass (−0.6%; 95% CI, −2.5% to 1.3%). Age-specific prevalence of sensitization to house dust mite and cat did not differ between year-of-birth cohorts, but sensitization to grass was most prevalent in the most recent ones. Overall, total IgE levels decreased significantly (geometric mean ratio, 0.63; 95% CI, 0.58-0.68) at all ages in all year-of-birth cohorts. Conclusion Aging was associated with lower levels of sensitization, especially to house dust mite and cat, after the age of 20 years.
Collapse
Affiliation(s)
- André F S Amaral
- Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom.
| | - Roger B Newson
- Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom; Department of Primary Care and Public Health, School of Public Health, Imperial College, London, United Kingdom
| | - Michael J Abramson
- School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
| | - Josep M Antó
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Roberto Bono
- Department of Public Health and Pediatrics, University of Turin, Turin, Italy
| | - Angelo G Corsico
- Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation-University of Pavia, Pavia, Italy
| | - Roberto de Marco
- Unit of Epidemiology and Medical Statistics, Department of Public Health and Community Medicine, University of Verona, Verona, Italy
| | - Pascal Demoly
- Department of Pulmonology, Division of Allergy, Arnaud de Villeneuve Hospital, CHU Montpellier, and EPAR Team-UMR-S 1136 INSERM, Paris, France
| | - Bertil Forsberg
- Division of Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
| | - Thorarinn Gislason
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Respiratory Medicine and Sleep, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland
| | - Joachim Heinrich
- Institute of Epidemiology I, Helmholtz Zentrum, Munich, Germany; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital Munich, Ludwig-Maximilians-Universität of Munich, Munich, Germany
| | - Ismael Huerta
- Epidemiological Surveillance Section, Directorate General of Public Health, Department of Health of Asturias, Oviedo, Spain
| | - Christer Janson
- Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
| | - Rain Jõgi
- Tartu University Hospital, Lung Clinic, Tartu, Estonia
| | - Jeong-Lim Kim
- Department of Publich Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - José Maldonado
- Unit of Clinical Management of Pneumology and Allergy, University Hospital of Huelva, Huelva, Spain
| | | | - Catherine Neukirch
- INSERM UMR1152, Paris, France; Université Paris Diderot Paris 7, UMR1152, Paris, France
| | - Dennis Nowak
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital Munich, Ludwig-Maximilians-Universität of Munich, and the German Center for Lung Research, Munich, Germany
| | - Isabelle Pin
- Pédiatrie, Pole Couple Enfants, CHU de Grenoble, Grenoble, France; INSERM U823, Institut Albert Bonniot, Grenoble, France; Université Joseph Fourier, Grenoble, France
| | - Nicole Probst-Hensch
- Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland
| | | | - Cecilie Svanes
- Centre for International Health, University of Bergen, Bergen, Norway; Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway
| | | | - Ronald van Ree
- Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Serge A Versteeg
- Department of Experimental Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Joost Weyler
- Epidemiology and Social Medicine and the StatUA Statistics Centre, University of Antwerp, Antwerp, Belgium
| | - Jan-Paul Zock
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Peter G J Burney
- Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
| | - Deborah L Jarvis
- Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
| |
Collapse
|
36
|
Gouel-Chéron A, Neukirch C, Aubier B, Montravers P, Nicaise P, Chollet-Martin S, Mertes PM, Aubier M, Longrois D. Anaphylactic bronchospasm during general anesthesia is not related to asthma. Allergy 2015; 70:453-6. [PMID: 25556961 DOI: 10.1111/all.12565] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2014] [Indexed: 10/24/2022]
Abstract
In the general population, a history of asthma (HA) is associated with a higher risk of mortality of anaphylactic shock (AS), but it is unknown whether this association remains valid for intra-operative AS. The goal of this retrospective study was to investigate whether a HA was associated with a higher risk of bronchospasm during intra-operative AS. We analyzed 106 patients (January 2009-December 2012) with intra-operative AS: 57% of them had a confirmed IgE-mediated reaction and 27% had a HA. On logistic regression, the only factor statistically associated with bronchospasm was a neuromuscular blocking drug, with both IgE- or non-IgE-mediated reactions. These results suggest that the mechanisms of bronchospasm in AS may be different from those of asthma and that, in the presence of bronchospasm during anesthesia, AS should be considered to be the most likely cause.
Collapse
Affiliation(s)
- A. Gouel-Chéron
- Département d'Anesthésie-Réanimation; Hôpital Bichat-Claude Bernard; Paris France
| | - C. Neukirch
- Service de Pneumologie; Hôpital Bichat-Claude Bernard; Paris France
| | - B. Aubier
- Département d'Anesthésie-Réanimation; Hôpital Bichat-Claude Bernard; Paris France
| | - P. Montravers
- Département d'Anesthésie-Réanimation; Hôpital Bichat-Claude Bernard; Paris France
| | - P. Nicaise
- Laboratoire d'Immunologie “Auto-Immunité et Hypersensibilités”; Hôpital Bichat-Claude Bernard; Paris France
| | - S. Chollet-Martin
- Laboratoire d'Immunologie “Auto-Immunité et Hypersensibilités”; Hôpital Bichat-Claude Bernard; Paris France
| | - P.-M. Mertes
- Service d'Anesthésie-Réanimation; Nouvel Hôpital Civil, CHU de Strasbourg; Strasbourg France
| | - M. Aubier
- Service de Pneumologie; Hôpital Bichat-Claude Bernard; Paris France
| | - D. Longrois
- Département d'Anesthésie-Réanimation; Hôpital Bichat-Claude Bernard; Paris France
| |
Collapse
|
37
|
Justet A, Neukirch C, Poubeau P, Arrault X, Borie R, Dombret MC, Crestani B. Successful rapid tocilizumab desensitization in a patient with Still disease. The Journal of Allergy and Clinical Immunology: In Practice 2014; 2:631-2. [DOI: 10.1016/j.jaip.2014.04.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 04/24/2014] [Accepted: 04/28/2014] [Indexed: 10/25/2022]
|
38
|
Ezratty V, Guillossou G, Neukirch C, Dehoux M, Koscielny S, Bonay M, Cabanes PA, Samet JM, Mure P, Ropert L, Tokarek S, Lambrozo J, Aubier M. Repeated nitrogen dioxide exposures and eosinophilic airway inflammation in asthmatics: a randomized crossover study. Environ Health Perspect 2014; 122:850-5. [PMID: 24747297 PMCID: PMC4123022 DOI: 10.1289/ehp.1307240] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Accepted: 04/15/2014] [Indexed: 05/05/2023]
Abstract
BACKGROUND Nitrogen dioxide (NO2), a ubiquitous atmospheric pollutant, may enhance the asthmatic response to allergens through eosinophilic activation in the airways. However, the effect of NO2 on inflammation without allergen exposure is poorly studied. OBJECTIVES We investigated whether repeated peaks of NO2, at various realistic concentrations, induce changes in airway inflammation in asthmatics. METHODS Nineteen nonsmokers with asthma were exposed at rest in a double-blind, crossover study, in randomized order, to 200 ppb NO2, 600 ppb NO2, or clean air once for 30 min on day 1 and twice for 30 min on day 2. The three series of exposures were separated by 2 weeks. The inflammatory response in sputum was measured 6 hr (day 1), 32 hr (day 2), and 48 hr (day 3) after the first exposure, and compared with baseline values measured twice 10-30 days before the first exposure. RESULTS Compared with baseline measurements, the percentage of eosinophils in sputum increased by 57% after exposure to 600 ppb NO2 (p = 0.003) but did not change significantly after exposure to 200 ppb. The slope of the association between the percentage of eosinophils and NO2 exposure level was significant (p = 0.04). Eosinophil cationic protein in sputum was highly correlated with eosinophil count and increased significantly after exposure to 600 ppb NO2 (p = 0.001). Lung function, which was assessed daily, was not affected by NO2 exposure. CONCLUSIONS We observed that repeated peak exposures of NO2 performed without allergen exposure were associated with airway eosinophilic inflammation in asthmatics in a dose-related manner.
Collapse
|
39
|
Chaisemartin L, Lim S, Neukirch C, Thetis M, Nicaise‐Roland P, Peltier S, Chollet‐Martin S. T cell activation in biological diagnosis of amoxicillin delayed hypersensitivity. Clin Transl Allergy 2014. [PMCID: PMC4128425 DOI: 10.1186/2045-7022-4-s3-p28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
| | - Suzy Lim
- APHPBichat Claude‐Bernard HospitalImmunology UnitFrance
| | | | | | | | - Sandy Peltier
- APHPBichat Claude‐Bernard HospitalImmunology UnitFrance
| | | |
Collapse
|
40
|
Schwab C, Gasperi E, Neukirch C, Tesmoingt C, Arnaud P, Arrault X. PP-032 Design of tocilizumab desensitisation protocol after a hypersensitivity reaction. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.330] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
41
|
Fottner C, Rossmann H, Bickmann JK, Sollfranck S, Hassoun R, Neukirch C, Papaspyrou K, Mann WJ, Schneider-Rätzke B, Bartsch D, Lackner KJ, Weber MM. Definition of a new algorithm for molecular-genetic testing of patients with hereditary pheochromocytoma and paraganglioma syndromes. Exp Clin Endocrinol Diabetes 2013. [DOI: 10.1055/s-0033-1336695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
42
|
Häuser F, Deyle C, Berard D, Neukirch C, Glowacki C, Bickmann JK, Wenzel JJ, Lackner KJ, Rossmann H. Macrophage-stimulating protein polymorphism rs3197999 is associated with a gain of function: implications for inflammatory bowel disease. Genes Immun 2012; 13:321-7. [PMID: 22237417 DOI: 10.1038/gene.2011.88] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Crohn's disease and ulcerative colitis, the two main types of inflammatory bowel disease (IBD), were reported to be associated with a variety of genetic polymorphisms. A subset of these polymorphisms was identified in both diseases and only three of them were found in primary sclerosing cholangitis (PSC). rs3197999 (Arg689Cys) located in the MST1 gene is one of the most convincingly replicated IBD/PSC-associated polymorphisms but its functional consequences have not been investigated, yet. We expressed both MST1 gene variants (Arg(689) (MSP(wt)) and Cys(689) (MSP(mut)) in a eukaryotic cell system and compared their stimulatory effects on macrophage-like THP-1 cells. Except for the rate of apoptosis that remained unchanged, MSP(mut) significantly increased the stimulatory effect of MSP (macrophage-stimulating protein) on chemotaxis and proliferation by THP-1 cells, indicating a gain of function associated with the Arg689Cys exchange. A broad set of evidence reported previously suggests that pro-inflammatory changes in macrophage function have a major role in the initiation of the inflammatory process in IBD and PSC. Therefore, the gain of function observed with rs3197999 in MST1 might provide a cellular mechanism for the consistent association of this polymorphism with an increased risk for IBD and PSC.
Collapse
Affiliation(s)
- F Häuser
- Institute of Clinical Chemistry and Laboratory Medicine, University Medical Centre Mainz, Mainz, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
A 35-year-old patient received omalizumab (300 mg twice a month) for 2 years for a severe atopic keratoconjunctivitis (AKC) in order to reduce the risk for steroid-induced keratitis. After 4 months, quality of life and ocular symptoms improved, and the use of oral steroids was strongly reduced. The treatment was well tolerated. This observation suggests that omalizumab may be a good option for the treatment of severe AKC, especially to avoid side effects of immunosuppressive treatments, as suggested for other allergic diseases. Specific trials should be designed for allergic eye diseases.
Collapse
|
44
|
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, Wjst M, Cerveri I, Pin I, Bousquet J, Jarvis D, Burney PG, Neukirch F, Leynaert B. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049-57. [PMID: 18805333 DOI: 10.1016/s0140-6736(08)61446-4] [Citation(s) in RCA: 390] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND A close relation between asthma and allergic rhinitis has been reported by several epidemiological and clinical studies. However, the nature of this relation remains unclear. We used the follow-up data from the European Community Respiratory Health Survey to investigate the onset of asthma in patients with allergic and non-allergic rhinitis during an 8.8-year period. METHODS We did a longitudinal population-based study, which included 29 centres (14 countries) mostly in western Europe. Frequency of asthma was studied in 6461 participants, aged 20-44 years, without asthma at baseline. Incident asthma was defined as reporting ever having had asthma confirmed by a physician between the two surveys. Atopy was defined as a positive skin-prick test to mites, cat, Alternaria, Cladosporium, grass, birch, Parietaria, olive, or ragweed. Participants were classified into four groups at baseline: controls (no atopy, no rhinitis; n=3163), atopy only (atopy, no rhinitis; n=704), non-allergic rhinitis (rhinitis, no atopy; n=1377), and allergic rhinitis (atopy+rhinitis; n=1217). Cox proportional hazards models were used to study asthma onset in the four groups. FINDINGS The 8.8-year cumulative incidence of asthma was 2.2% (140 events), and was different in the four groups (1.1% (36), 1.9% (13), 3.1% (42), and 4.0% (49), respectively; p<0.0001). After controlling for country, sex, baseline age, body-mass index, forced expiratory volume in 1 s (FEV(1)), log total IgE, family history of asthma, and smoking, the adjusted relative risk for asthma was 1.63 (95% CI 0.82-3.24) for atopy only, 2.71 (1.64-4.46) for non-allergic rhinitis, and 3.53 (2.11-5.91) for allergic rhinitis. Only allergic rhinitis with sensitisation to mite was associated with increased risk of asthma independently of other allergens (2.79 [1.57-4.96]). INTERPRETATION Rhinitis, even in the absence of atopy, is a powerful predictor of adult-onset asthma.
Collapse
Affiliation(s)
- Rafea Shaaban
- Unit 700 Epidemiology, National Institute of Health and Medical Research (INSERM), Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
BACKGROUND Desloratadine is associated with decreased signs and symptoms and improved nasal airflow in multiple clinical trials in patients with allergic rhinitis (AR). The effect of desloratadine on quality of life (QOL) in AR has not been widely reported to date. We compared the effects of desloratadine and placebo on QOL in seasonal AR using validated, disease-specific measures. METHODS This was a multicenter, double-blind, randomized, parallel-group study of desloratadine 5 mg or placebo daily for 2 weeks in patients with symptomatic seasonal AR. QOL was assessed at baseline and at day 14 using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). AR signs/symptoms and the global response to therapy were measured at baseline and at day 14; signs/symptoms were also rated AM/PM in patient diaries. Adverse events (AE) were recorded. RESULTS Overall 234 patients received desloratadine and 249 received placebo. At day 14 desloratadine was associated with a significantly larger improvement from baseline in the mean total RQLQ score vs placebo (P = 0.0003). Desloratadine also led to significant improvements from baseline in all RQLQ sub-domains (P < or = 0.043). At day 14 significant decreases from baseline were noted in the desloratadine group for total nasal (P = 0.0003), total non-nasal (P = 0.001) and total symptoms scores (P = 0.0001). Morning AR symptoms were significantly decreased in the desloratadine group after 1 day of treatment. Desloratadine was well tolerated, with an AE rate similar to placebo. CONCLUSION Significant reductions in signs and symptoms of AR with desloratadine treatment were accompanied by improved disease-specific QOL measures.
Collapse
Affiliation(s)
- A Pradalier
- Department of Internal Medicine, Hôpital Louis Mourier, Colombes Cedex, France
| | | | | | | |
Collapse
|
46
|
Shaaban R, Zureik M, Soussan D, Neukirch C, Neukirch F F, Leynaert B. 002 Allergic rhinitis and risk of adult-onset asthma: a longitudinal European population-based study. Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)74294-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Abstract
Strong data are lacking on the cross-reactivity between individual carbapenems. We describe a 48-year-old woman with ventilator-associated Pseudomonas aeruginosa pneumonia who received an 8-day course of imipenem-cilastatin and experienced a delayed (i.e., nonimmediate) hypersensitivity reaction, evidenced by an extensive erythematous macular morbilliform rash and an increased eosinophil count. Eight days after completion of therapy, the pneumonia returned, and it was decided to avoid using imipenem-cilastatin; she was administered a 14-day course of meropenem. To our knowledge, this is the first report of a nonimmediate hypersensitivity reaction to imipenem-cilastatin without cross-reactivity to meropenem. This suggests that if carbapenem therapy is unavoidable, meropenem may be cautiously administered in patients with a known allergy to imipenem-cilastatin.
Collapse
Affiliation(s)
- Karim Lakhal
- Services de Réanimation Médicale et Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France.
| | | | | | | | | |
Collapse
|
48
|
Höhn H, Kortsik C, Zehbe I, Hitzler WE, Kayser K, Freitag K, Neukirch C, Andersen P, Doherty TM, Maeurer M. MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD4+ T cells in peripheral blood from patients with pulmonary tuberculosis. Scand J Immunol 2007; 65:467-78. [PMID: 17444958 DOI: 10.1111/j.1365-3083.2007.01924.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Novel diagnostic tools are needed to diagnose latent infection and to provide biologically meaningful surrogate markers to define cellular immune responses against Mycobacterium tuberculosis (MTB). Interferon gamma-based assays have recently been developed in addition to the more than 100-year-old tuberculin skin test (TST) for the immune diagnosis of MTB in blood. The advent of soluble MHC/peptide tetramer molecules allows to objectively enumerate antigen-specific T cells. We identified novel MHC class II-restricted MTB epitopes and used HLA-DR4 tetrameric complexes to visualize ex vivo CD4(+) T cells directed against the antigens Ag85B and the 19-kDa lipoprotein, shared between MTB and other Mycobacterium species, and CD4(+) T cells which recognize the MTB-associated ESAT-6 antigen. MTB-reactive CD4(+) T cells reside predominantly in the CD45RA(+) CD28(+) and CD45(-) CD28(+) T-cell subset and recognize naturally processed and presented MTB epitopes. HLA-DR4-restricted, Ag85B or ESAT-6-specific CD4(+) T cells show similar dynamics over time in peripheral blood mononuclear cells (PBMC) when compared with CD8(+) T cells directed against the corresponding HLA-A2-presented MTB epitopes in patients with pulmonary MTB infection and subsequent successful therapy. This was not found to be true for T-cell responses directed against the 19-kDa lipoprotein. The dissection of the cellular immune response in M. tuberculosis infection will enable novel strategies for monitoring MTB vaccine candidates and to gauge CD4(+) T cells directed against MTB.
Collapse
Affiliation(s)
- H Höhn
- Department of Medical Microbiology, University of Mainz, Hochhaus Augustusplatz, Mainz, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ezratty V, Bonay M, Neukirch C, Orset-Guillossou G, Dehoux M, Koscielny S, Cabanes PA, Lambrozo J, Aubier M. Effect of formaldehyde on asthmatic response to inhaled allergen challenge. Environ Health Perspect 2007; 115:210-4. [PMID: 17384766 PMCID: PMC1817692 DOI: 10.1289/ehp.9414] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2006] [Accepted: 11/07/2006] [Indexed: 05/04/2023]
Abstract
BACKGROUND Exposure to formaldehyde may lead to exacerbation of asthma. OBJECTIVES Our aim in this study was to investigate whether exposure to a low level (500 microg/m(3)) of formaldehyde enhances inhaled allergen responses. METHODS Twelve subjects with intermittent asthma and allergy to pollen were exposed, at rest, in a double-blind crossover study to either formaldehyde or purified air for 60 min. The order of exposure to formaldehyde and air-only was randomized, and exposures were separated by 2 weeks. We also performed an allergen inhalation challenge after each exposure. Airway responsiveness to methacholine and lower airway inflammation (induced sputum) were assessed 8 hr after allergen challenge. RESULTS The median dose of allergen producing a 15% decrease in forced expiratory volume in 1 sec (PD(15)FEV(1)) was 0.80 IR (index of reactivity) after formaldehyde exposure compared with 0.25 IR after air-only exposure (p = 0.06). Formaldehyde exposure did not affect allergen-induced increase in responsiveness to methacholine (p = 0.42). We found no formaldehyde-associated effect on the airway inflammatory response, in particular the eosinophilic inflammatory response, induced by the allergen challenge 8 hr before. CONCLUSION In this study, exposure to 500 microg/m(3) formaldehyde had no significant deleterious effect on airway allergen responsiveness of patients with intermittent asthma; we found a trend toward a protective effect.
Collapse
Affiliation(s)
- Véronique Ezratty
- Service des Etudes Médicales d'EDF et de Gaz de France, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Herry I, Neukirch C, Debray MP, Mignon F, Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007; 18:76-7. [PMID: 17223050 DOI: 10.1016/j.ejim.2006.07.017] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2006] [Revised: 05/24/2006] [Accepted: 07/06/2006] [Indexed: 10/23/2022]
Abstract
Angiomyolipomas are very common in patients with tuberous sclerosis complex (TSC) and cause substantial morbidity. Until now, arterial embolization has been the recommended treatment for symptomatic patients. We report the case of a woman with TSC and giant angiolipomas in whom sirolimus induced a dramatic reduction in bilateral renal tumors.
Collapse
Affiliation(s)
- Isabelle Herry
- Service de pneumologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France, Université Paris 7, France
| | | | | | | | | |
Collapse
|